WO2002016905A2 - Near infrared blood glucose monitoring system - Google Patents
Near infrared blood glucose monitoring system Download PDFInfo
- Publication number
- WO2002016905A2 WO2002016905A2 PCT/US2001/025810 US0125810W WO0216905A2 WO 2002016905 A2 WO2002016905 A2 WO 2002016905A2 US 0125810 W US0125810 W US 0125810W WO 0216905 A2 WO0216905 A2 WO 0216905A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patient
- blood glucose
- spectral
- invasive
- remote
- Prior art date
Links
- 239000008103 glucose Substances 0.000 title claims abstract description 193
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 192
- 239000008280 blood Substances 0.000 title claims abstract description 174
- 210000004369 blood Anatomy 0.000 title claims abstract description 174
- 238000012544 monitoring process Methods 0.000 title claims description 14
- 230000003595 spectral effect Effects 0.000 claims abstract description 160
- 238000004458 analytical method Methods 0.000 claims abstract description 24
- 230000008929 regeneration Effects 0.000 claims abstract description 10
- 238000011069 regeneration method Methods 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 57
- 239000000470 constituent Substances 0.000 claims description 32
- 238000005259 measurement Methods 0.000 claims description 22
- 238000010200 validation analysis Methods 0.000 claims description 22
- 230000003287 optical effect Effects 0.000 claims description 16
- 238000004364 calculation method Methods 0.000 claims description 14
- 230000005540 biological transmission Effects 0.000 claims description 12
- 238000009499 grossing Methods 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 230000006870 function Effects 0.000 claims description 9
- 238000012937 correction Methods 0.000 claims description 8
- 230000001172 regenerating effect Effects 0.000 claims description 7
- 238000012417 linear regression Methods 0.000 claims description 6
- 238000010606 normalization Methods 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 3
- 238000012628 principal component regression Methods 0.000 claims description 3
- 238000012306 spectroscopic technique Methods 0.000 claims description 3
- 238000013528 artificial neural network Methods 0.000 claims description 2
- 238000007620 mathematical function Methods 0.000 claims 5
- 230000001131 transforming effect Effects 0.000 claims 1
- 238000001228 spectrum Methods 0.000 description 23
- 206010012601 diabetes mellitus Diseases 0.000 description 22
- 238000002834 transmittance Methods 0.000 description 20
- 238000004891 communication Methods 0.000 description 16
- 230000005855 radiation Effects 0.000 description 14
- 239000013078 crystal Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000002835 absorbance Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000010586 diagram Methods 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 6
- 238000004445 quantitative analysis Methods 0.000 description 6
- 208000013016 Hypoglycemia Diseases 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 210000003811 finger Anatomy 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 238000000985 reflectance spectrum Methods 0.000 description 5
- 210000003813 thumb Anatomy 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 229910003069 TeO2 Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 229940056932 lead sulfide Drugs 0.000 description 3
- 229910052981 lead sulfide Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012806 monitoring device Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- LAJZODKXOMJMPK-UHFFFAOYSA-N tellurium dioxide Chemical compound O=[Te]=O LAJZODKXOMJMPK-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000001742 aqueous humor Anatomy 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 235000021004 dietary regimen Nutrition 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 229910052738 indium Inorganic materials 0.000 description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 239000010937 tungsten Substances 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000016311 Freckling Diseases 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229910003327 LiNbO3 Inorganic materials 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241001026602 Quintana Species 0.000 description 1
- -1 Tungsten Halogen Chemical class 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- XCAUINMIESBTBL-UHFFFAOYSA-N lead(ii) sulfide Chemical compound [Pb]=S XCAUINMIESBTBL-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000001320 near-infrared absorption spectroscopy Methods 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000001055 reflectance spectroscopy Methods 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/28—Investigating the spectrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1495—Calibrating or testing of in-vivo probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/02—Details
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/02—Details
- G01J3/0205—Optical elements not provided otherwise, e.g. optical manifolds, diffusers, windows
- G01J3/0232—Optical elements not provided otherwise, e.g. optical manifolds, diffusers, windows using shutters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/02—Details
- G01J3/0205—Optical elements not provided otherwise, e.g. optical manifolds, diffusers, windows
- G01J3/0235—Optical elements not provided otherwise, e.g. optical manifolds, diffusers, windows using means for replacing an element by another, for replacing a filter or a grating
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/02—Details
- G01J3/0205—Optical elements not provided otherwise, e.g. optical manifolds, diffusers, windows
- G01J3/0237—Adjustable, e.g. focussing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/02—Details
- G01J3/0205—Optical elements not provided otherwise, e.g. optical manifolds, diffusers, windows
- G01J3/0254—Spectrometers, other than colorimeters, making use of an integrating sphere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/02—Details
- G01J3/0289—Field-of-view determination; Aiming or pointing of a spectrometer; Adjusting alignment; Encoding angular position; Size of measurement area; Position tracking
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/02—Details
- G01J3/10—Arrangements of light sources specially adapted for spectrometry or colorimetry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/12—Generating the spectrum; Monochromators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
- G01N21/359—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/12—Generating the spectrum; Monochromators
- G01J2003/1213—Filters in general, e.g. dichroic, band
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/12—Generating the spectrum; Monochromators
- G01J3/18—Generating the spectrum; Monochromators using diffraction elements, e.g. grating
- G01J2003/1828—Generating the spectrum; Monochromators using diffraction elements, e.g. grating with order sorter or prefilter
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/28—Investigating the spectrum
- G01J2003/2866—Markers; Calibrating of scan
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2201/00—Features of devices classified in G01N21/00
- G01N2201/06—Illumination; Optics
- G01N2201/065—Integrating spheres
Definitions
- the present invention relates to the field of near infrared spectrometry for predicting patient blood glucose levels.
- Diabetes Mellitus There are roughly four million people in the United States currently diagnosed with Diabetes Mellitus. This disease causes blindness, loss of extremities, heart failure, and other complications over time. There is no “cure” for the disease, which is caused by either the failure of the pancreas to produce insulin or the body's inability to use insulin, but rather only treatment, most commonly with insulin injections in order to change the blood-glucose level.
- Type I diabetes As well as people with Type II diabetes or diagnosed as pre-diabetic, need to frequently monitor their blood glucose levels, establishing an individual blood glucose profile in order to adjust diet, medication, exercise, or to lower the blood glucose while avoiding hypoglycemia (low blood-sugar).
- hypoglycemia low blood-sugar
- two or three blood samples are tested for glucose daily and are usually sufficient.
- blood samples may be required in rapid (every few minutes) succession.
- Tests for blood glucose levels consist of obtaining blood by venipuncture or pricking an extremity (usually a finger) to draw a drop of blood .
- This blood sample is inserted into an analytical device (e.g., Accu-Check ® , Hemo-Cue ® , Diasensor 1000 ® , Corning Express 550 ® , Roche Cobas Mira ® , or Ektachem (R)DT60 ⁇ Analyzer ® ).
- the device may be an electrochemical detector that monitors reaction of glucose oxidase with glucose in the blood. The current or voltage is measured, and resulting data is displayed as a concentration, typically milligrams per deciliter (mg/dL).
- Another means of measuring glucose is by measuring the absorbance of the reaction at 540 nm. It is often difficult, particularly in elderly or infant patients, to perform the necessary measurement, particularly when needed several times a day.
- NIR near-infrared
- Infrared spectrometry is a technique that is based upon the vibrational changes of the atoms of a molecule.
- an infrared spectrum is generated by transmitting infrared radiation through a sample of an organic substance and determining the portions of the incident radiation that are absorbed by the sample.
- An infrared spectrum is a plot of absorbance (or transmittance) against wavenumber, wavelength or frequency.
- Infrared radiation is radiation having a wavelength between about 750 nm and about 1000 ⁇ m.
- Near-infrared radiation is radiation having a wavelength between about 750 nm and about 2500 nm.
- spectrometers A variety of different types are known in the art such as grating spectrometers, FT (Fourier transformation) spectrometers, Hadamard transformation spectrometers, AOTF (Acousto Optical Tunable Filter) spectrometers, diode array spectrometers, filter-type spectrometers, scanning dispersive spectrometers and nondispersive spectrometers.
- grating spectrometers FT (Fourier transformation) spectrometers, Hadamard transformation spectrometers, AOTF (Acousto Optical Tunable Filter) spectrometers, diode array spectrometers, filter-type spectrometers, scanning dispersive spectrometers and nondispersive spectrometers.
- FT Fastier transformation
- AOTF Acoustic Optical Tunable Filter
- Filter-type spectrometers utilize an inert solid heated to provide continuous radiation (e.g., tungsten filament lamp) to illuminate a rotating opaque disk, wherein the disk includes a number of narrow bandpass optical filters. The disk is then rotated so that each of the narrow bandpass filters passes between the light source and the sample.
- An encoder indicates which optical filter is presently under the light source. The filters filter light from the light source so that only a narrow selected wavelength range passes through the filter to the sample.
- Optical detectors are positioned so to as detect light that either is reflected by the sample (to obtain a reflectance spectra) or is transmitted through the sample (to generate a transmittance spectra). The amount of detected light is then measured and provides an indication of the amount of absorbance of the light by the substance under analysis.
- Diode Array spectrometers use infrared emitting diodes (IREDs) as sources of near-infrared radiation.
- IREDs infrared emitting diodes
- a plurality of (for example, eight) IREDs are arranged over a sample work surface to be illuminated for quantitative analysis.
- Near-infrared radiation emitted from each IRED impinges upon an accompanying optical filter.
- Each optical filter is a narrow bandpass filter that passes NIR radiation at a different wavelength.
- NIR radiation passing through the sample is detected by a detector (such as a silicon photodetector). The amount of detected light is then measured and provides an indication of the amount of absorbance of the light by the substance under analysis.
- Acousto Optical Tunable Filter spectrometers utilize an RF signal to generate acoustic waves in a TeO 2 crystal.
- a light source transmits a beam of light through the crystal, and the interaction between the crystal and the RF signal splits the beam of light into three beams: a center beam of unaltered white light and two beams of monochromatic and orthogonally polarized light.
- a sample is placed in the path of one of the monochromatic beam detectors, which are positioned to detect light that either is reflected by the sample (to obtain a reflectance spectra) or is transmitted through the sample (to generate a transmittance spectra).
- the wavelength of the light source is incremented across a wavelength band of interest by varying the RF frequency.
- the amount of detected light is then measured and provides an indication of the amount of absorbance of the light by the substance under analysis.
- a light source transmits a beam of light through an entrance slit and onto a diffraction grating (the dispersive element) to disperse the light beam into a plurality of beams of different wavelengths (i.e., a dispersed spectrum).
- the dispersed light is then reflected back through an exit slit onto a detector.
- the wavelength of the light directed to the detector can be varied.
- the amount of detected light is then measured and provides an indication of the amount of absorbance of the light by the substance under analysis.
- the width of the entrance and exit slits can be varied to compensate for any variation of the source energy with wavenumber.
- a nondispersive infrared filter photometer is designed for quantitative analysis of various organic substances.
- the wavelength selector comprises: a filter as previously described to control wavelength selection; a source; and a detector.
- the instrument is programmed to determine the absorbance of a multicomponent sample at wavelengths and then to compute the concentration of each component.
- spectrometers have been used to measure the chemical composition of blood and, more particularly, blood glucose.
- the mean blood glucose level varies within a normal range of 70- 120 mg/dL from person to person. For diabetics, these fluctuations can vary markedly, reaching values of 200-400 mg/dL within a very short time in accordance with their food intake, physical activity, a complication by another disease, or the like.
- the majority of patients with Type I diabetes, as well as people with Type II diabetes or diagnosed as pre-diabetic need to frequently monitor their blood glucose levels, establishing an individual blood glucose profile in order to adjust diet, medication or exercise, or in order to lower the blood glucose while avoiding hypoglycemia (low blood-sugar).
- hypoglycemia low blood-sugar
- two or three blood samples are tested for glucose daily and are usually sufficient.
- blood samples may be required in rapid (every few minutes) succession.
- United States Patent No. 5,961,449 to Toida et al. purports to disclose a method and apparatus for non-invasive measurement of the concentration of glucose in the aqueous humor in the anterior aqueous chamber of the eyeball, and a method and apparatus for non-invasive measurement of the concentration of glucose in the blood in accordance with the concentration of glucose in the aqueous humor.
- Known near-infrared analytical techniques using multivarient analysis are utilized therein.
- United States Patent No. 5,910,109 to Peters et al. allegedly describes a glucose measuring device for determining the concentration of intravascular glucose in a subject including: a light source having a wavelength of 650, 880, 940 or 1300 nm to illuminate the fluid; receptors associated with the light sources for receiving light and generating a transmission signal representing the light transmitted and adapted to engage a body part of a subject; and a signal analyzer, which includes a trained neural network for determining the glucose concentration in the blood of the subject.
- This reference purportedly also provides a method for detennining the glucose concentration, which method includes calibration of a measuring device and setting of an operating current for illuminating the light sources during operation of the device.
- the high and low values from each of the signals are stored in the device and are averaged to obtain a single transmission value for each of the light sources.
- the averaged values are then analyzed to determine the glucose concentration, which then is displayed.
- United States Patent No. 5,935,062 to Messerschmidt et al. purports to describe a specular control device that can discriminate between diffusely reflected light that is reflected from selected depths or layers within the tissue by receiving the diffusely reflected light that is reflected from a first layer or depth within the tissue, while preventing the remaining diffusely reflected light from reaching the spectroscopic analyzer.
- This patent allegedly describes a method for obtaining diffuse reflectance spectra from human tissue for the non-invasive measurement of blood analytes, such as blood glucose by collecting the infrared energy that is reflected from a first depth and rejecting the infrared energy that is reflected from a second.
- United States Patent No. 5,941,821 to Chou allegedly provides an apparatus for more accurate measurement of the concentration of a component in blood (e.g., glucose), including a source for irradiating a portion of the blood by heat-diffusion to generate acoustic energy propagating in a second medium over a surface of the blood in response to the irradiation, a detector for detecting the acoustic energy and for providing an acoustic signal in response to the acoustic energy, and a processor for determining the concentration of the component in response to the acoustic signal and characteristics of the component.
- a component in blood e.g., glucose
- a modeling equation (often referred to as a calibration model) that reflects the individual patient's blood glucose profile is generated by scanning a number of blood glucose samples to generate a set of calibration data, and then processing the data to obtain the modeling equation.
- the recalibration procedure involves scanning a set of calibration samples and analyzing those same samples with a primary technique, such as High Performance Liquid Chromatography (HPLC), to adjust the modeling equation.
- HPLC High Performance Liquid Chromatography
- a dynamic modeling equation is one that provides a way to recalculate the equation when the model no longer accurately reflects the patient's glucose profile.
- a dynamic model is accomplished by scanning the subject with a noninvasive spectroscopic blood glucose monitor and then using an invasive technique (e.g., venipuncture or a fingerstick) to obtain a constituent value to associate with the spectral data. This procedure must be repeated a number of times in order to obtain a sufficient number of spectral data scans and associated constituent values to develop a robust and accurate modeling equation for the individual patient.
- the frequency and amount of recalibration needed is dependent on the amount of variation in the individual subject's blood glucose values.
- additional spectral scans and associated constituent values are obtained from the patient, and the modeling equation is regenerated using the original data along with the new data.
- the original data is found to be unsuitable (for example, due to significant change in the patient's condition)
- this recalibration is required on a weekly basis, a significant reduction in the amount of invasive monitoring has been achieved.
- a truly dynamic modeling equation would seemingly require a highly trained and experienced individual using an advanced statistics computer program to evaluate the modeling equation and to perform the mathematics required to maintain the modeling equation. It is impractical, however, to have a scientist directly consult with each patient to maintain his or her individual modeling equation. This is especially true if development of a hand-held, remote spectral device for home use is desired.
- a dynamic modeling equation can predict the patient's blood glucose level using a noninvasive spectral scan obtained from a remote spectral device (preferably handheld).
- a spectral scan is obtained from a patient and sent to a central computer.
- a central computer stores the generated spectral scan along with a previously generated patient modeling equation for that patient.
- a resultant blood glucose level is calculated for that patient based on his or her individual modeling equation. If the spectral scan falls within the range of the modeling equation, a blood glucose value is predicted and the predicted blood glucose level is output to the patient. If the spectral scan falls outside the range of the modeling equation, regeneration of the model is required, and the patient is instructed to take a number of noninvasive scans, followed by an invasive blood glucose level determination. All of the data is then transferred to the central computer where the modeling equation is regenerated based on both the existing data points and the new data points.
- a preferred method for generating and updating the modeling equation is set forth in more detail below.
- the central computer uses a complex statistics computer program to generate a new modeling equation, thereby allowing for much of this task to be automated.
- a new modeling equation is generated as needed, for example in cases of a change in medical condition that affects the blood glucose levels or as instructed by the manufacturer (e.g., once a month).
- the remote spectral device communicates with the central computer by any conventional mode of data transmission, such as a cellular data link, a telephone modem, a direct satellite link, or an Internet link.
- the remote spectral device maybe directly linked to the invasive blood glucose monitor by an appropriate data connection, such as an RS233 data comiection, but preferably both the sensor and monitor are contained in the same unit along with a handheld computer, similar to a PALM PILOT TM .
- additional messages can be sent from the central computer to the remote spectral device, for example, reminders to the patient to obtain blood glucose levels or to take medication. It may also be desirable to include other data inputs from the patient, such as blood pressure, heart rate and temperature, which data will be fransmittable from the remote spectral device to the central computer.
- the central processing unit further communicates the relevant information received from the patient and any instructions transmitted to the patient via the remote spectral device to the patient's doctor or hospital.
- a method for predicting blood glucose values in a patient by: generating an individualized modeling equation for a patient as a function of non-invasive spectral scans of a body part of the patient and an analysis of blood samples from the patient, and storing the individualized modeling equation on a central computer; receiving from the patient a non-invasive spectral scan generated by a remote spectral device; predicting a blood glucose value for the patient as a function of the non-invasive spectral scan and the individualized modeling equation, and transmitting the predicted blood glucose value to the patient; detennining that a regeneration of the individualized modeling equation is required, and transmitting a request for a set of non invasive spectral scans and a corresponding set of blood glucose values to the patient; acquiring a set of noninvasive spectral scans from the
- FIG. 1 is a simplified schematic showing the basic elements of the present invention and the interaction between the same.
- FIG. 2 A is a basic schematic of transmittance spectrometer
- FIG 2B is a basic schematic of reflectance spectrometer.
- FIG. 3 is a diagram of an instrument detector system used for diffuse reflectance spectroscopy.
- FIG. 4 is a schematic representation of diffuse reflectance using an integrating sphere sample presentation geometry.
- FIG. 5 is a diagram of a turret-mounted interference filter instrument.
- FIG. 6 shows a rotating tilting filter wheel utilizing wedge interference filters.
- FIG. 7 shows a spinning filter system in which the light passes through an encoder wheel.
- FIG. 8 is a diagram of a grating monochromator spectrometer, with Figure 8 A showing a side view and Figure 8B a top view of the grating instrument.
- FIG. 9 shows a typical predispersive monochromator-based instrument in which the light is dispersed prior to striking the sample.
- FIG. 10 shows a post-dispersive monochromator-based instrument in which the light is dispersed after striking the sample.
- FIG. 11 illustrates an Acousto Optical Tunable Filter spectrometer.
- FIGS. 12A and 12B illustrates a noninvasive near IR spectral device that can be used for obtaining spectral scans.
- FIG. 12C illustrates another non-invasive near IR spectral device that can be used for obtaining spectral scans.
- FIG. 13A illustrates the blood glucose profile of an elderly diabetic Afro- American female (patient OMF).
- FIG. 13B illustrates a modeling equation of near infrared values versus noninvasive glucose values using a Hemo-Cue ® system for patient OMF.
- FIG. 13C illustrates a comparison of NTR glucose values (dashed line) versus Hemo-Cue ® system glucose values (solid line) for patient OMF.
- FIG. 14A illustrates the blood glucose profile over five weeks of a middle-age diabetic Caucasian female (patient MLM).
- FIG. 14B illustrates a modeling equation of near infrared values versus noninvasive glucose values using a Hemo-Cue ® system for patient MLM.
- FIG. 14C illustrates a comparison of NTR glucose values (dashed line) versus Hemo-Cue ® system glucose values (solid line) for patient MLM.
- FIG. 15A illustrates the blood glucose profile over five weeks of a middle-age diabetic Caucasian female (patient SLH).
- FIG. 15B illustrates a modeling equation of near infrared values versus noninvasive glucose values using a Hemo-Cue ® system for patient SLH.
- FIG. 15C illustrates a comparison of NTR glucose values (dashed line) versus Hemo-Cue ® system glucose values (solid line) for patient SLH.
- FIG. 16 A illustrates the blood glucose profile over five weeks of a middle-age diabetic Afro-American male (patient TFD).
- FIG. 16B illustrates a modeling equation of near infrared values versus noninvasive glucose values using a Hemo-Cue ® system for patient TFD.
- FIG. 16C illustrates a comparison of NTR glucose values (dashed line) versus Hemo-Cue ® system glucose values (solid line) for patient TFD.
- FIG. 17A illustrates the blood glucose profile over five weeks of a young diabetic Caucasian male (patient BDD).
- FIG. 17B illustrates a modeling equation of near infrared values versus noninvasive glucose values using a Hemo-Cue ® system for patient BDD
- FIG. 17C illustrates a comparison of NTR glucose values (dashed line) versus
- FIG. 18A illustrates the blood glucose profile over five weeks of a young Caucasian female (patient PFK), used as a control subject.
- FIG. 18B illustrates a modeling equation of near infrared values versus noninvasive glucose values using a Hemo-Cue ® system for patient PFK.
- FIG. 18C illustrates a comparison of NTR glucose values (dashed line) versus Hemo-Cue ® system glucose values (solid line) for patient PFK.
- FIGS. 19A-B are tables of transform pairs used when data is collected by diffuse reflectance, wherein FIG. 19A depicts the first transform versus second transforms, and FIG. 19B depicts the ratio transform pairs.
- FIGS. 20A-B are tables of transform pairs used when data is collected by diffuse- transmittance, wherein FIG. 20A depicts the first transform versus second transforms, and FIG. 20B depicts the ratio transform pairs.
- FIGS. 21A-B are tables of transform pairs used when data is collected by clear transmittance, wherein FIG. 21 A depicts the first transform versus second transforms, and
- FIG. 2 IB depicts the ratio transform pairs.
- FIG. 22 is a table of derivative spacing factors.
- a system for non-invasive monitoring of blood glucose levels to create an individualized blood glucose profile is provided, wherein a patient can accurately predict the current status of his/her blood glucose levels and obtain immediate feedback on any corrective measures needed in the maintenance thereof.
- Figure 1 sets forth the preferred interconnection between the various parts of a preferred embodiment of the present invention.
- a remote communication link is provided between a conventional invasive blood glucose monitoring device 1 (e.g., Accu-chek ® blood glucose monitor or any other electrochemical analytical instrument), a non-invasive spectroscopic device 2 and a central computer 3.
- a further remote communication link is provided between the central computer 3 and the primary doctor's office or hospital 4.
- the central computer stores the spectral scan from noninvasive device 2, the data obtained using invasive blood glucose monitor 1 and a modeling equation for each individual patient.
- measurements of a patient's blood glucose levels are taken at predetermined intervals over a predetermined period of time using both the spectral device 2 and conventional invasive glucose monitoring methods. Intervals and sampling times as well as monitoring methods are well known to those of skill in the art. See, for example, Tietz, Norbert, Fundamentals of Clinical Chemistry (1976) Saunders Company,
- a constituent value is a reference value for blood glucose in the sample, which reference value is measured by an independent measurement technique comprising the use of an invasive method (e.g., Hemo-Cue ® device).
- an invasive method e.g., Hemo-Cue ® device.
- the spectral data obtained by noninvasive means for each sample has associated therewith at least one constituent value for that sample.
- the set of spectral scans (with its associated constituent values) is divided into a calibration subset and a validation subset.
- the calibration subset is selected to represent the variability likely to be encountered in the validation subset.
- a plurality of data transforms is then applied to the set of spectral scans.
- the transforms are applied singularly and two-at-a-time.
- the particular transforms that are used and the particular combination pairs that are used are selected based upon the particular method that is being used to analyze the spectral data (e.g. diffuse reflectance, clear transmission, or diffuse transmission as discussed in the detailed description).
- the plurality of transforms applied to the spectral data includes at least a second derivative and a baseline correction.
- transforms include, but are not limited to the following: performing a nonnalization of the spectral data, performing a ratio on the spectral data, performing a first derivative on the spectral data, performing a second derivative on the spectral data, performing a multiplicative scatter correction on the spectral data, and performing smoothing transforms on the spectral data.
- both the normalization transform and the multiplicative scatter correction transform also inherently perform baseline corrections.
- transforms are defined as follows:
- NULL transform is defined, for the purposes of the present invention, as making no change to the data as originally collected.
- NORMALIZ transform is defined, for purposes of the present invention, as a normalization transform (normalization), hi accordance with this transform, the mean of each spectrum is subtracted from each wavelength's value for that spectrum, then each wavelength's value is divided by the standard deviation of the entire spectrum. The result is that each transformed spectrum has a mean of zero and a standard deviation of unity.
- FIRSTDRV transform is defined, for purposes of the present invention, as performing a first derivative in the following manner.
- An approximation to the first 5 derivative of the spectrum is calculated by taking the first difference between data at nearby wavelengths.
- a spacing parameter together with the actual wavelength spacing in the data file, controls how far apart the wavelengths used for this calculation are. Examples of spacing parameters include but are not limited to the values 1, 2, 4, 6, 9, 12, 15, 18, 21 and 25.
- a spacing value of 1 (unity) causes adjacent wavelengths to be used for the calculation.
- the resulting value of the derivative is assumed to correspond to a wavelength halfway between the two wavelengths used in the computation. Since derivatives of wavelengths too near the ends of the spectrum cannot be computed, the spectrum is truncated to eliminate those wavelengths. If, as a result of wavelength editing or a prior data transform there is insufficient data in a given range to compute the derivative, then that range is
- the value of the spacing parameter is varied such that a FIRSTDRV transform includes a plurality of transforms, each having a different spacing parameter value.
- SECNDDRV transform is defined, for purposes of the present invention, as performing a second derivative by talcing the second difference (i.e., the difference • 20 between data at nearby wavelengths of the FIRSTDRV) as an approximation to the second derivative.
- the spacing parameters, truncation and other considerations described above with regard to the FIRSTDRV apply equally to the SECNDDRV.
- the second derivative preferably includes variable spacing parameters.
- MULTSCAT transform is defined, for purposes of the present invention, 25 as Multiplicative Scatter Correction.
- Multiplicative Scatter Correction is applied to the spectra in the calibration set, then it should also be applied to future samples before using their spectral data in the modeling equation. It is the mean spectrum for the calibration set that continues to provide the standard to which spectra are fitted.
- the MSC may be applied to correction for log 1/R spectra or Kubelka-Munk data for example. See, Osborne, B.G., Fearn, T. and Hindle, P.H., Practical NTR Spectroscopy, With Applications in Food and Beverage Analysis (2 nd edition, Longman Scientific and Technical) (1993).
- SMOOTHNG transform is defined, for purposes of the present invention, as a smoothing transform that averages together the spectral data at several contiguous wavelengths in order to reduce the noise content of the spectra.
- a smoothing parameter specifies how many data points in the spectra are averaged together. Examples of values for smoothing parameters include but are not limited to values of 2, 4, 8, 16 and 32.
- a smoothing value of 2 causes two adjacent wavelengths to be averaged together, and the resulting value of the smoothed data is assumed to correspond to a wavelength halfway between the two end wavelengths used in the computation. Since wavelengths too near the ends of the spectrum cannot be computed, the spectrum is truncated to eliminate those wavelengths.
- the smoothing parameter value is varied such that a smoothing transform includes a plurality of smoothing transforms, each having a different smoothing parameter.
- RATIO transform is defined, for purposes of the present invention, as a transform that divides a numerator by a denominator.
- the data to be used for numerator and denominator are separately and independently transformed. Neither numerator or denominator may itself be a ratio transform, but any other transform is permitted.
- exemplary transform pairs that can be performed during the automatic search are described in Figures 19A (diffuse reflectance), 20A (diffuse transmittance) and 21 A (clear transmittance). It should be noted that when "NULL" is selected for both transforms, the original data is used unchanged. The format of the original data is assumed by the system to be absorbency data (i.e., log 1/T or log 1/R).
- exemplary combinations of transforms that can be used for the RATIO transform are illustrated in Figures 19B (diffuse reflectance), 20B (diffuse transmittance) and 21B (clear transmittance). If a ratio transform is specified, then numerator and denominator data sets are transformed individually.
- one or more algorithms are then performed on the transformed and untransformed (i.e., Null transform) calibration data sets to obtain corresponding modeling equations for predicting the amount of blood glucose in a sample.
- the algorithms include at least a multiple linear regression analysis (MLR calculations may, for example, be performed using software from The Near Infrared Research Corporation, 21 Terrace Avenue, Suffern, N.Y. 10901) and, most preferably, a Partial Least Squares and
- the modeling equations are ranked to select a best model for analyzing the spectral data, h this regard, for each sample in the validation subset, the system determines, for each modeling equation, how closely the value returned by the modeling equation is to the constituent value(s) for the sample.
- the best modeling equation is the modeling equation that across all of the samples in the validation subset, returned the closest values to the constituent values: i.e., the modeling equation that provided the best correlation to the constituent values.
- the values are ranked according to a Figure of Merit (described in equations 1 and 2 below).
- the FOM is defined as
- FOM (without Bias) FOM ⁇ J (SEE 2 + 2 * SEP 2 ) 13 2.
- FOM (with Bias) FOM ⁇ (SEE 2 + 2 * SEP 2 + W*tf) I (3 + W)
- SEE is the Standard Error of Estimate from the calculations on the calibration data
- SEP is the Standard Error of Estimate from the calculations on the validation data
- b is the bias of the validation data (bias being the mean difference between the predicted values and corresponding constituent values for the constituent)
- W is a weighting factor for the bias.
- SEE is the standard deviation, corrected for degrees of freedom, for the residuals due to differences between actual values (which, in this context, are the constituent values) and the MR predicted values within the calibration set (which, in this context, are the values returned by applying the spectral data in the calibration subset, which corresponds to the constituent values, to the modeling equation for which the FOM is being calculated).
- SEP is the standard deviation for the residuals due to differences between actual values (which, in this context, are the constituent values) and the NTR predicted values outside the calibration set (which, in this context, are the values returned by applying the spectral data in the validation subset, which corresponds to the constituent values, to the modeling equation for which the FOM is being calculated).
- the best modeling equation is stored on the central computer, where this modeling equation is used to relate future noninvasive spectroscopic readings to a blood glucose level. Specifically, when the patient acquires a spectral scan using the remote noninvasive spectral device, the spectral scan is transmitted to the central computer where the modeling equation obtained for the individual patient is used to predict the blood glucose level from the spectral scan. If the spectral scan falls within the range of the modeling equation, the blood glucose level is output to the patient.
- the central computer allows for much of this task to be automated in the manner described above.
- the invasive blood glucose monitor and remote spectral device may be separate units capable of communicating with the central computer, preferably the invasive blood glucose monitor is capable of communicating the data obtained from the invasive patient blood samples to the remote spectral device, which in turn forwards this information to the central computer.
- the spectral data may be communicated to the invasive blood glucose monitor which in turn forwards this information onto the central computer.
- Information from both the spectral unit and invasive unit can be transmitted via any conventional mode of communication (e.g., a cellular data link, a telephone connection, a direct satellite link or an Internet link) to the central computer for analysis.
- the remote spectral device is directly linked to the invasive blood glucose monitor by an appropriate data connection.
- the remote spectral device has a communication port, such as an RS232 communication port, that is connected to the invasive blood glucose monitor (e.g., an Accu-Check ® blood glucose monitor).
- the invasive blood glucose monitor e.g., an Accu-Check ® blood glucose monitor.
- the invasive blood glucose monitor and remote spectral device are interfaced with a remote computer capable of communication with the central computer, for example a desktop workstation, laptop or a hand-held computer such as a PALM PILOT TM .
- a remote computer capable of communication with the central computer
- the central computer for example a desktop workstation, laptop or a hand-held computer such as a PALM PILOT TM .
- Communication between the invasive blood glucose monitor, the remote spectral device, the remote computer and the central computer can be implemented by any known mode of communication.
- both the remote spectral device and the invasive blood glucose monitor have communication ports (such as a RS 232 port) that connect to the remote computer.
- the invasive blood glucose monitor and remote spectral device are contained within a single unit, preferably a portable unit containing a microprocessor and an associated communications interface for communicating with the central computer (similar in design to a PALM PILOT TM hand-held computer).
- the portable unit may be configured to communicate with a remote computer that, in turn, communicates with the central computer.
- the portable unit or remote computer is preferably capable of receiving additional information from the patient for submission to the central computer via the transmission methods identified above. For example, it may be desirable to transmit further information from the patient such as a temperature, blood pressure, heart rate, patient exercise regimen or dietary regimen, h certain embodiments, the portable unit or remote computer is capable of storing the modeling equation and of performing the calculation of the glucose concentration information using the spectral data.
- any conventional method of invasive blood glucose monitoring may be used in conjunction with spectral scans obtained using the remote spectral device.
- testing may be conducted in a doctor's office or hospital setting using venipuncture to withdraw blood from the patient at predetermined intervals.
- Such techniques can be accomplished with such commercially available instruments as the Diasensor 1000 ® , Corning Express 550 ® , Roche Cobas Mira ® and Ektachem (R)DT60II Analyzer ® .
- blood measurements are obtained by the patient using a suitable self monitoring invasive glucose monitor, such as an Accu- Check ® blood glucose monitor, a Yellow Springs Instrument ® or a Hemo-Cue ® blood glucose monitor.
- these invasive glucose monitors are electrochemical detectors that monitor reaction of glucose oxidase with glucose in the blood.
- the current or voltage is measured, and resulting data is displayed as concentration, typically in milligrams per deciliter (mg/dL).
- concentration typically in milligrams per deciliter (mg/dL).
- the patient draws blood from a finger tip using a lancet and places the blood on a chemical test strip that is then inserted into the monitor for analysis.
- the instrument measures the glucose level in the blood and digitally displays the glucose level.
- the remote spectral device is preferably attached to a body part, such as a finger, ear lobe, base of the thumb or other area of the body for which a diffuse reflectance scan in the spectral region of 500nm to 3000nm is taken, h certain preferred embodiments, the body part to be tested is the palm of the person's hand or the sole of the foot. It is thought that these body parts, which are less often subjected to direct sunlight and therefore tend to have fewer signs of sun damage such as freckling and tanning, may thereby provide more accurate results.
- measurements are conducted at predetermined intervals (e.g., morning and evening) over a predetermined period of time (e.g., 4-6 weeks) using both the remote noninvasive spectral device and the invasive blood glucose monitor.
- a predetermined period of time e.g., 4-6 weeks
- the patient would obtain readings from both the remote spectral device and from the invasive blood glucose monitor once a week, over the course of a number of weeks (e.g., a five-week period of time).
- the information received by virtue of these readings is then forwarded to the central computer for storage and ultimately for use in the calibration of an appropriate algorithm (modeling equation) once sufficient data is received.
- the calibration is also suitable for the calibration to be conducted in a doctor's office or in a hospital setting using the remote spectral device and a suitable invasive means for measuring blood glucose levels, with such information being sent to the central computer for storage of the information and for calculation of the modeling equation.
- the modeling equation may be calculated by a scientist but preferably is conducted to large extent by the central computer, with a scientist overseeing and approving the results of the central computer's calculations. Most preferably, the modeling equation is generated by using a plurality of modeling equations that are generated in the manner described above.
- the equation is downloaded to the remote microprocessor (e.g., a remote computer or a processor that is integrated into the spectral device), where it is stored and used for predicting the blood glucose level of the patient until a new modeling equation becomes necessary (e.g., after the onset of a disease that affects blood glucose levels or at specified intervals).
- the modeling equation is stored only in the central computer, and the spectral scan is merely transmitted to the central computer for analysis. Status checks of the system are conducted on a regular basis (e.g., every two to four weeks).
- the patient simultaneously collects approximately five spectral scans and invasive blood glucose levels and sends them to the central computer for regeneration of a modeling equation.
- the five additional data points are added to the existing data, and a new modeling equation is generated using both the new and old data.
- the prediction of the blood glucose value based on the spectral data using the algorithm may be conducted at the central computer or may be conducted by a remote computer associated with the remote spectral device or a processor integrated into the spectral device. If the calculation is conducted by the remote computer, the spectral information is nevertheless transmitted to the central computer for evaluation of the algorithm to ensure that recalibration is not needed, and preferably also for evaluation of blood glucose levels.
- the unit containing the remote spectral device will be able to detect other nonspectral body properties ("non-spectral compensation data"), such as pulse rate, blood pressure and body temperature, that may interfere with the blood glucose spectral prediction.
- non-spectral compensation data can be determined separately by the patient and then be input into the unit containing the remote spectral device or the remote computer via a suitable transmission mechanism, such as a key board or voice recognition program, hi certain other embodiments, additional information of interest to the diabetic patient and doctor (such as food intake and exercise regimen) may be transmitted via the unit containing the remote spectral device or the remote computer to the central computer.
- the nonspectral compensation data may be incorporated into the modeling equations as auxiliary or indicator variables. A discussion of how such variables can incorporated can be found in U.S. Patent Application No. 09/636,041.
- the remote spectral device may control a drug pump, which can automatically administer the appropriate amount of a drug to the patient such as by means of an TV line or pre-inserted subdermal pump.
- spectrometers contemplated for use in association with the present invention for use as the noninvasive spectral device can be any of the known versions in the art including, but not limited to, the devices described below and with respect to Figures 2-11.
- spectrometers capable of being integrated into the remote spectral device include filter-type spectrometers, diode array spectrometers, AOTF (Acousto Optical Tunable Filter) spectrometers, grating spectrometers, FT (Fourier transfonnation) spectrometers, Hadamard transformation spectrometers and scanning dispersive spectrometers.
- the spectral device is preferably a handheld device including both the source of NTR radiation and the detector, larger instrumentation may also be suitable provided that the unit can easily be situated in the user's home and can be transported with the user when necessary.
- a detailed description of examples of several suitable spectrometers follows.
- Figures 2A-B show the two most prevalent basic instrument design's common in modern near-infrared analysis: transmittance spectrometers and reflectance spectrometers.
- Figure 2A is a basic schematic diagram of a transmittance spectrometer
- Figure 2B is a basic schematic diagram of a reflectance spectrometer.
- a monochromator 12 produces a light beam 15 having a desired narrow band of wavelengths from light 18 emitted from a light source 11, and the light beam 15 is directed onto a sample 13.
- the detector(s) 14 are positioned to detect the light 16 that is transmitted through the sample 13, and, in the case of a reflectance spectrometer, the detector(s) 14 are positioned to detect the light 17 that is reflected off the sample 13.
- a spectrometer may or may not be used as both a transmittance and a reflectance spectrometer.
- the light source utilized in the remote spectral device is preferably a Quartz Tungsten Halogen bulb or an LED (Light Emitting Diode), although any suitable light source, including a conventional light bulb, may be used.
- Suitable detectors for use in the analysis of the radiation include silicon (Si), indium/antimony (friSb), indium/gallium/arsenic (friGaAs) and lead sulfide (PbS).
- silicon Si
- indium/antimony friSb
- indium/gallium/arsenic friGaAs
- lead sulfide detectors are used for measurements in the 1100- 2500-nm region
- lead sulfide "sandwiched" with silicon photodiodes are used for visible-near-infrared applications (typically 400-2600 nm).
- Figure 3 is a diagram of an instrument detector system used for diffuse reflectance.
- the geometry of this system provides for monochromatic light 1 to illuminate the sample 13 (i.e., a body part of a patient such as the palm of the hand or the heel of the foot, or another sample that may be held by sample holder 14) at a 90°angle (normal incidence) to the sample.
- the collection detectors 26 comprise photo cells 25 for detecting the reflected light, each of which is at a 45 ° angle to window 24. Two or four detectors, each at a 45 ° angle, can be used.
- the spectrometer may include an integrating sphere such as the one set forth in Figure 4.
- Figure 4 a schematic representation of diffuse reflectance using an integrating sphere sample presentation geometry is shown. Within the integrating sphere 30 are shown a reference beam 31 and an illuminating beam 32 that hits the sample 13 and is deflected 34 off to the detectors 35.
- "sweet spots" existed on photomultiplier tubes of the detector and early semiconductor and photodiode detectors that made reproducible measurements using detectors very difficult, if not impossible.
- the integrating sphere cured this problem by protecting the detector from being susceptible to energy fluctuations from the incident beam because of deflection (scattering), refraction or diffraction of light when working in the transmittance mode, hi modern applications, the use of the integrating sphere provides for internal photometric referencing, producing a sort of pseudo-double-beam instrument.
- Single-beam instruments must be set up to measure a reference material before or after the sample scans are taken, requiring inconvenience on the part of the user.
- Figure 5 shows a split-beam spectrometer.
- Light is transmitted from the light source 51 through the filter 52 (which is shown as being turret-mounted) to a mirror 53 that is positioned to angle the light and create a split-beam, with one resulting beam 54 acting as a reference beam to a first detector 55 and a second resulting beam 57 passing through or reflecting off the sample 13 to a second detector 56.
- the difference in the amount of detected light at the second detector is compared to the amount of light at the first detector.
- Nondispersive infrared filter photometers are designed for quantitative analysis of various organic substances.
- the wavelength selector comprises: a filter, as previously described, to control wavelength selection; a source; and a detector.
- the instrument is programmed to determine the absorbance of a multicomponent sample at wavelengths and then to compute the concentration of each component.
- Figures 6 and 7 illustrate two basic forms of filter-type NTR spectrometer utilizing a tilting filter arrangement.
- Figure 6 shows a nondispersive infrared filter photometer designed for quantitative analysis of various organic substance.
- This device utilizes a light source 41, such as the conventional light bulb shown in the figure, to illuminate 42 a rotating opaque wheel 48, wherein the disk includes a number of narrow bandpass optical filters 44.
- the wheel is then rotated so that each of the narrow bandpass filters passes between the light source and a sample 13.
- the wheel 48 controls which optical filter 44 is presently before the light source.
- the filters 44 filter the light from the light source 41 so that only a narrow selected wavelength range passes through the filter to the sample 13.
- Optical detectors 46 are positioned to detect light that either is reflected by the sample (to obtain a reflectance spectra, as illustrated with detectors 46) or is transmitted through the sample (to generate a transmittance spectra, as illustrated with detector 47). The amount of detected light is then measured, thereby providing an indication of the amount of absorbance of the light by the substance under analysis.
- Figure 7 shows a rotating encoder wheel 143 utilizing wedge interference filters 144 for blocking light.
- Light 142 is transmitted through the encoder wheel 143 at varying wavelengths and bandpass, dependent on the incident angle of the light passing through the interference filter 144 to the sample 13.
- Optical detectors 46 are positioned to detect light that either is reflected by the sample (to obtain a reflectance spectra, as illustrated with detectors 46) or is transmitted through the sample (to generate a transmittance spectra, as illustrated with detector 47). The amount of detected light is then measured, providing an indication of the amount of absorbance of the light by the substance under analysis.
- Figures 8A and 8B illustrate a grating monochrometer.
- light is transmitted from a source 61 containing a condenser lens 62 through an entrance lens 63 to a variable entrance slit 64 where the beams of light 65 are deflected to a folding mirror 66.
- the mirror sends the beam of light to a grating 67, which in turn projects the light through an exit slit 68 to an exit lens 69.
- the light then passes through a filter wheel 70 containing aperatures 71 to an objective lens 72 and then on to a rotating mirror 73.
- the rotating mirror 73 has a dark/open chopper 74, a chopper sensor 75, a dark blade(s) 76 and a reference mirror 77 capable of sending a reference beam.
- the light is transmitted from the rotating mirror through a sphere window lens 79 and a sample window 78 to the sample 13, which then reflects the light to detector(s) 80.
- FIG. 8(B) a top view of the grating instrument is shown, wherein light passes through the exit slit 81 to the grating 82 which projects the beam 83 to a folding mirror 84, from which it is projected to a variable entrance slit 85.
- Figure 9 shows a schematic diagram of typical pre-dispersive monochromator-based instrument in which the light is dispersed prior to striking the sample.
- the light source 91 transmits a beam of light 92 through an entrance slit 93 and onto a grating 94.
- the grating 94 separates the light into a plurality of beams of different wavelengths.
- a desired band of wavelengths is selected for transmission to the sample 13.
- this spectrometer may also be used with both transmittance detectors and reflectance detectors 46.
- Figure 10 shows a schematic diagram of a typical post-dispersive monochromator. This type of instrument provides the advantage of allowing the transmission of more energy on the sample via either a single fiberoptic strand or a fiberoptic bundle.
- white light is piped through the fiberoptic strand or fiberoptic bundle 101 and onto the sample 13.
- the light is then reflected 102 off the sample 13 and back to the grating 103 (the dispersive element).
- the grating 103 the dispersive element
- the light is separated into the various wavelengths by order sorting 105 and stds 106 prior to striking a detector 104.
- the post-dispersive monochromator can be used with reflectance detectors.
- the dedicated dispersive (grating-type) scanning NTR instruments vary in optical design but generally have the common features of tungsten-halogen source lamps, single monochromator with a holographic diffraction grating, and uncooled lead sulfide detectors.
- Figure 11 depicts an Acousto Optical Tunable Filter spectrometer utilizing an RF signal 201 to generate acoustic waves in a TeO 2 crystal 202.
- a light source 203 transmits a beam of light through the crystal 202, and the interaction between crystal 202 and RF signal 201 splits the beam of light into three beams: a center beam of unaltered white light 204 and two beams of monochromatic 205 and orthogonally 206 polarized light.
- a sample 13 is placed in the path of one of the monochromatic beams.
- the wavelength of the light source is incremented across a wavelength band of interest by varying the RF frequency.
- an acoustic transducer 207 is bonded on one surface of the specially cut crystal.
- the acoustic transducer is a piezoelectric material, such as LiNbO 3 driven by 1-4 W of radio frequency (RF) coupled into the transducer.
- the high-frequency (30-200 MHz) acoustic waves induce index of refraction waves in the acoustooptical material.
- the waves travel through the crystal very quickly.
- the acoustic waves "fill" the crystal, interacting with the broad-band light traveling through the crystal.
- the angles of the crystal axis, the relative angles of the broad-band light into three beams.
- the center beam is the unaltered white light traveling through the crystal.
- the TeO 2 material has virtually no absorption from the visible spectrum all the way to about 5 ⁇ m.
- the two new beams generated by the acoustically excited crystal are, as discussed above, monochromatic and orthogonally polarized. These beams are used as monochromatic light sources for analytical purposes.
- the main advantage of the AOTF optics is that the wavelength is electronically selected without the delays associated with mechanical monochromators.
- the electronic wavelength selection allows a very high-duty cycle because almost no time is wasted between wavelength switching, hi comparison with "fast-scanning" instruments, the advantage is not only that the scanning rate is orders of magnitude faster but also that the wavelength access is random.
- the AOTF instrument is able to select those and is not confined to accessing all wavelengths serially (as in fast grating monochromators) or multiplexed (as in FT-NTR).
- the AOTF instruments generally are much smaller than grating monochromators but with equal resolution, h a properly engineered design, the long-term wavelength repeatability also surpasses that of the grating monochromator.
- Figures 12A and 12B depict a preferred remote spectrometer 300 for performing noninvasive spectral scans of a sample 13 (i.e., the base of the thumb) to predict blood glucose levels.
- sample portion 301 includes a light emitting portion 304 and a plurality of detectors 305 surrounding light emitting portion 304.
- light emitting portion 301 of the sample module is connected by a fiber optic cable 303 to the monochrometer 302 comprising a light source and a grating for selecting desired wavelength (e.g., 1100-2500 nm).
- a communication module 309 receives specfral scans from the detectors 305 in sample portion 301 and transmits the spectral scan data to a remote computer (not shown).
- the communication module may also be configured to store the spectral scan data for subsequent use.
- the spectrometer 300' of Figure 12C is similar to the spectrometer 300 of Figures 12A and 12B, except that light emitting portion 304 is located above the five detectors 305, and the sample 13 (in this case, the base of the thumb) is placed between light emitting portion 304 and detectors 305.
- the remote computer obtains the spectral scan, the spectral scan will then be stored in the memory on the computer. The remote computer will then automatically access the central computer, establish a communication link and then upload the spectral scan to the central computer.
- the remote spectrometer 300 itself may itself include a processor, a memory and a communications port for uploading the spectral data to the cenfral computer.
- the central computer is preferably a server or workstation capable of holding spectral databases for a plurality of patients.
- the workstation is preferably configured to allow multiple clients to concurrently access the server. Any known WAN networking technology may be used to promote this functionality.
- the cenfral computer will store: 1) all spectral data collected from that client; 2) all constituent data from that client (from the invasive blood-monitoring device); and 3) the current modeling equation that is being used to predict the blood glucose level from the specfral scan, h preferred embodiments, the central computer also stores non-spectral compensation data and may further store additional information submitted by the patient, such as dietary intake and exercise regimen.
- the central computer receives a plurality of spectral scans from the spectral device (remote or otherwise) and associated constituent data (invasively- measured blood glucose levels) from an invasive measurement device, and calculates the modeling equation from which future blood glucose levels will be predicted, preferably using the preferred technique discussed above.
- the central computer then receives spectral data from a remote specfral device and, if the spectral scan is within the range of the modeling equation, predicts a blood glucose value from the modeling equation and sends the blood glucose value back to the patient.
- the central computer may also alert the patient when, based on the spectral data, the modeling equation is no longer valid, and either sends a message to the patient to attempt another reading or sends a message to begin a recalibration procedure.
- the cenfral computer may also instruct the patient to begin a recalibration procedure at regular intervals (e.g., once a month). Once recalibration is initiated, the patient will perform a number of specfral scans and corresponding invasive measurements (to obtain constituent values) at designated times.
- the spectral data and constituent values are uploaded to the central computer, and the cenfral computer then regenerates the modeling equation based on the original data as well as on the data uploaded during the recalibration procedure.
- the cenfral computer transmits the appropriate timing schedule to the patient via communication with the remote computer or the remote spectrometer 300. i this regard, additional instructions, such as medication schedules, may be transmitted to the patient in the same manner.
- the central computer regenerates a modeling equation for an individual patient, as described above and transmits the modeling equation to the portable unit containing a microprocessor and spectral device (and preferably an acceptable invasive blood glucose monitor).
- the patient can then conduct further noninvasive testing on a pre-determined schedule, with the portable unit itself predicting the individual's blood glucose using the modeling equation previously downloaded from the central computer.
- the spectral data can then be subsequently sent to the central computer for analysis. If the specfral data is not within an acceptable parameter a message is sent to the patient to regenerate (i.e., recalibrate) a modeling equation.
- the determination of whether the data is within acceptable parameters may be made by the portable unit itself, or alternatively by the central computer.
- Regeneration can also be initiated at regular predetermined intervals (such as monthly). As described above, regeneration may be initiated either partially or fully with new data, depending on the particular situation.
- the central computer is capable of transmitting basic instructions to the patient to obtain blood glucose levels or to take medication, hi further embodiments, more complicated instructions can be sent to the patient, such as instructions to call the patient's doctor for reevaluation of medication or instructions to adjust medication regimen, diet or exercise.
- the data received by the central processing unit and the data sent back to the remote spectral device is time/date stamped and is secured (e.g., encrypted, requiring a key to decipher, or transmitted over a dedicated line and requiring a password for access).
- the unit containing the remote spectral device or a remote computer
- all information obtained during the scanning is nevertheless submitted to the central computer for analysis and to ensure that regeneration of the modeling equation is not necessary.
- the operation of the central computer and the maintenance of the models from each patient are preferably overseen by trained staff members.
- the central computer is further connected to one or more doctor's offices, hospitals or other patient care facilities, such as a nursing home or hospice.
- the doctor may contact the central computer to obtain information regarding the blood glucose levels of the relevant patients or can request individual information regarding patients, hi a preferred embodiment, the doctor is able to obtain information concerning patient information, such as heart rate, pulse, blood pressure, dietary intake and exercise regimen.
- blood glucose information is automatically transmitted to the doctor by the central computer upon completion of the cenfral computer's receipt and analysis of a particular patient's information (e.g., STAT samples).
- a particular patient's information e.g., STAT samples
- the blood glucose information for all patients in the system is automatically transmitted to the patient's doctor at regular intervals, preferably twice a day.
- other relevant patient information such as heart rate and blood pressure, also are automatically transmitted to the doctor.
- the doctor is capable of transmitting instructions concerning patient care to the central computer, which instructions are both stored by the central computer in the patient's file and transmitted by the central computer to the patient's remote computer as a message.
- the central computer is associated with a website through which the data can be accessed by the patient and/or physician.
- the website may contain further information relating to disease state, including referral service, articles of interest, links to hospitals and links to diabetes related associations, h further embodiments, diabetes related equipment and supplies can be purchased through the website.
- the website contains or is linked to a remote licensed pharmacy capable of receiving prescriptions and filling prescriptions.
- access to a patient's records is obtained through a secure line by entering a predesignated password
- patient information supplemental to blood glucose levels such as information on exercise and dietary regimen, heart rate and pulse, can be digitally transmitted to the website by modem or by e-mail.
- the method of the present invention although described above in terms of the measurement of blood glucose, can also be used to predict any known clinical chemistry, hematology, or immunology body fluid parameters, including, e.g., insulin levels. Examples
- readings were performed at various times in relation to eating.
- the first reading was taken in the morning following a fast of at least eight hours.
- the patients ate a full meal.
- the second reading was taken at approximately 30 minutes after eating.
- Subsequent readings were taken approximately every 30 minutes up to and including 150 minutes after eating for a total of six readings (in some instances, a seventh reading was taken at 180 minutes after eating).
- the near IR reading was taken with a model AP 1365-11 Rapid Content Analyzer (RCA system), including a Model 6500 scanning Near-h frared spectrometer. Each patient placed the base of his/her thumb on the Rapid Content Sample Module of the device
- the RCA system was manufactured by FOSS-NTR Systems and has the following specifications:
- the patients in the clinical study have the following profiles:
- the spectral data and associated constituent values were randomly divided into a calibration set and a validation set, with approximately equal numbers of readings in each set.
- Two successive data transforms were then applied to the spectral data in the calibration and validation sets. The following is a list of the data transforms applied:
- Some of the transforms have parameters (e.g., spacing of data points for the first derivative, second derivative and smoothing transforms) associated with them.
- parameters e.g., spacing of data points for the first derivative, second derivative and smoothing transforms.
- the data transform is performed multiple times, using different values of the parameter.
- the values used for each data transform requiring a parameter are presented in Figure 22.
- the following algorithms were then applied to each set of transformed spectral scan: PLS (partial least squares), PCR (principal component regression), and MLR (multiple linear regression), thereby producing three equations for each set of transformed spectral scan.
- Each of the equations (or calibration models) is then applied to the specfral data in the validation set.
- FOM sj(SEE 2 + 2 * SEP 2 ) 13 , where: SEE is the Standard Error of Estimate from the calculations on the calibration data; and
- SEP is the Standard Error of Estimate from the calculations on the validation data.
- Table I summarizes the best modeling equation as calculated for each patient, based on the FOM, using the first four weeks of readings (unless otherwise indicated in the Patients Results Summary, infra). These modeling equations were then used to predict the fifth week readings. The results are summarized below with reference to Figures 13-18. TABLE I
- Figure 13 A shows the blood glucose profile of patient OMF, an elderly, female Afro-American diabetic, who is seen to be in control because her pattern is nearly identical each week of the five- week test.
- NTR calculated results were quite comparable with the reference values from the Hemo-Cue ® tester.
- a comparison of the NTR calculated values (dashed line) versus the Hemo-Cue ® reference values (solid line) is shown in Figure 13B.
- the values for the fifth week were calculated using an equation built from the first four weeks' data as an external validation test. That is, the spectral scans taken on the fifth week were analyzed by the modeling equation, and glucose values were generated. These values (dashed line) are compared with the reference (Hemo-Cue ® ) values (solid line) in Figure 13C. As can be seen, the rise and fall of the blood glucose is followed reasonably well. What is seen is the correlation to the invasive meter that is measuring glucose in blood, specifically, using an enzyme/electrochemical process.
- Figures 14A-C show the same experiment with a middle-aged female diabetic patient (MLM).
- MLM middle-aged female diabetic patient
- FIG 14A shows that patient MLM's pattern was nearly identical each week of the five- week test.
- Figure 14B shows a comparison of a Multiple Linear Regression equation generated for this patient based upon the NTR calculated values (dashed line) and based upon the Hemo-Cue ® reference values (solid line).
- Figure 14C shows close correlation of the external validation test, i.e., that the specfral scans taken on the fifth week were analyzed by the modeling equation, and the generated glucose values (dashed line) are quite close to the reference (Hemo-Cue ® ) values (solid line).
- the NTR calculated results were quite comparable with the reference values from the Hemo- Cue ® tester for patient MLM.
- FIG. 16A shows that the patient's blood glucose levels are recorded within a wide range from a high of 330 mg/dL on week 2 to a low of 44 mg/dL on week 5.
- the blood glucose level predicted at week 5 represents a lower than normal value often associated with hypoglycemia.
- Figure 18A shows blood glucose levels of a healthy person. While the validation comparison with reference values (Figure 18B) is not perfect, Figure 18C shows very nice agreement between calculated and reference values for the fifth week. (The y-axis scaled is greatly reduced for this normal, healthy subject.)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01968013A EP1311189A4 (en) | 2000-08-21 | 2001-08-17 | Near infrared blood glucose monitoring system |
AU2001288292A AU2001288292A1 (en) | 2000-08-21 | 2001-08-17 | Near infrared blood glucose monitoring system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22663700P | 2000-08-21 | 2000-08-21 | |
US60/226,637 | 2000-08-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002016905A2 true WO2002016905A2 (en) | 2002-02-28 |
WO2002016905A3 WO2002016905A3 (en) | 2002-08-01 |
Family
ID=22849764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/025810 WO2002016905A2 (en) | 2000-08-21 | 2001-08-17 | Near infrared blood glucose monitoring system |
Country Status (4)
Country | Link |
---|---|
US (1) | US6675030B2 (en) |
EP (1) | EP1311189A4 (en) |
AU (1) | AU2001288292A1 (en) |
WO (1) | WO2002016905A2 (en) |
Cited By (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003076893A2 (en) * | 2002-03-08 | 2003-09-18 | Sensys Medical, Inc. | Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers |
WO2006056024A1 (en) * | 2004-11-29 | 2006-06-01 | Scientific Analytics Systems Pty Ltd | Modelling a phenomenon that has spectral data |
US7299082B2 (en) | 2003-10-31 | 2007-11-20 | Abbott Diabetes Care, Inc. | Method of calibrating an analyte-measurement device, and associated methods, devices and systems |
US7728821B2 (en) | 2004-08-06 | 2010-06-01 | Touchtable, Inc. | Touch detecting interactive display |
US7811231B2 (en) | 2002-12-31 | 2010-10-12 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
WO2012049666A2 (en) | 2010-10-15 | 2012-04-19 | Verrana, Llc | Data word analysis by spectroscopy |
US8624863B2 (en) | 2004-08-06 | 2014-01-07 | Qualcomm Incorporated | Touch driven method and apparatus to integrate and display multiple image layers forming alternate depictions of same subject matter |
US8692792B2 (en) | 2004-08-06 | 2014-04-08 | Qualcomm Incorporated | Bounding box gesture recognition on a touch detecting interactive display |
US8937540B2 (en) | 2007-04-14 | 2015-01-20 | Abbott Diabetes Care Inc. | Method and apparatus for providing dynamic multi-stage signal amplification in a medical device |
US9031630B2 (en) | 2006-02-28 | 2015-05-12 | Abbott Diabetes Care Inc. | Analyte sensors and methods of use |
US9042953B2 (en) | 1998-04-30 | 2015-05-26 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9039975B2 (en) | 2006-03-31 | 2015-05-26 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
US9050041B2 (en) | 2009-10-30 | 2015-06-09 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
US9060719B2 (en) | 2007-05-14 | 2015-06-23 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9069536B2 (en) | 2011-10-31 | 2015-06-30 | Abbott Diabetes Care Inc. | Electronic devices having integrated reset systems and methods thereof |
US9066697B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066709B2 (en) | 2009-01-29 | 2015-06-30 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
US9078607B2 (en) | 2005-11-01 | 2015-07-14 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9088452B2 (en) | 2009-04-29 | 2015-07-21 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US9498159B2 (en) | 2001-01-02 | 2016-11-22 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9610046B2 (en) | 2008-08-31 | 2017-04-04 | Abbott Diabetes Care Inc. | Closed loop control with improved alarm functions |
US9615780B2 (en) | 2007-04-14 | 2017-04-11 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US9622691B2 (en) | 2011-10-31 | 2017-04-18 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
US9629578B2 (en) | 2006-10-02 | 2017-04-25 | Abbott Diabetes Care Inc. | Method and system for dynamically updating calibration parameters for an analyte sensor |
EP3128302A4 (en) * | 2014-04-01 | 2017-04-26 | Shimadzu Corporation | Spectrometer and integrating sphere |
US9636068B2 (en) | 2009-02-03 | 2017-05-02 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US9636450B2 (en) | 2007-02-19 | 2017-05-02 | Udo Hoss | Pump system modular components for delivering medication and analyte sensing at seperate insertion sites |
US9649057B2 (en) | 2007-05-08 | 2017-05-16 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US9662056B2 (en) | 2008-09-30 | 2017-05-30 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
US9675290B2 (en) | 2012-10-30 | 2017-06-13 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
US9687183B2 (en) | 2010-03-24 | 2017-06-27 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US9693713B2 (en) | 2011-12-11 | 2017-07-04 | Abbott Diabetes Care Inc. | Analyte sensor devices, connections, and methods |
US9730584B2 (en) | 2003-06-10 | 2017-08-15 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
US9730650B2 (en) | 2008-11-10 | 2017-08-15 | Abbott Diabetes Care Inc. | Alarm characterization for analyte monitoring devices and systems |
US9730623B2 (en) | 2008-03-28 | 2017-08-15 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US9743862B2 (en) | 2011-03-31 | 2017-08-29 | Abbott Diabetes Care Inc. | Systems and methods for transcutaneously implanting medical devices |
US9743863B2 (en) | 2006-03-31 | 2017-08-29 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
US9743865B2 (en) | 2007-10-23 | 2017-08-29 | Abbott Diabetes Care Inc. | Assessing measures of glycemic variability |
US9743872B2 (en) | 2011-11-23 | 2017-08-29 | Abbott Diabetes Care Inc. | Mitigating single point failure of devices in an analyte monitoring system and methods thereof |
US9750444B2 (en) | 2009-09-30 | 2017-09-05 | Abbott Diabetes Care Inc. | Interconnect for on-body analyte monitoring device |
US9750439B2 (en) | 2009-09-29 | 2017-09-05 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
US9770211B2 (en) | 2008-01-31 | 2017-09-26 | Abbott Diabetes Care Inc. | Analyte sensor with time lag compensation |
US9775563B2 (en) | 2005-09-30 | 2017-10-03 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
US9788771B2 (en) | 2006-10-23 | 2017-10-17 | Abbott Diabetes Care Inc. | Variable speed sensor insertion devices and methods of use |
US9795331B2 (en) | 2005-12-28 | 2017-10-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US9797880B2 (en) | 2007-05-14 | 2017-10-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9795326B2 (en) | 2009-07-23 | 2017-10-24 | Abbott Diabetes Care Inc. | Continuous analyte measurement systems and systems and methods for implanting them |
US9795328B2 (en) | 2008-05-30 | 2017-10-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US9804148B2 (en) | 2007-10-23 | 2017-10-31 | Abbott Diabetes Care Inc. | Analyte sensor with lag compensation |
US9804150B2 (en) | 2007-05-14 | 2017-10-31 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9801571B2 (en) | 2007-05-14 | 2017-10-31 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US9801545B2 (en) | 2007-03-01 | 2017-10-31 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
US9808186B2 (en) | 2006-09-10 | 2017-11-07 | Abbott Diabetes Care Inc. | Method and system for providing an integrated analyte sensor insertion device and data processing unit |
US9814416B2 (en) | 2009-08-31 | 2017-11-14 | Abbott Diabetes Care Inc. | Displays for a medical device |
US9814428B2 (en) | 2006-10-25 | 2017-11-14 | Abbott Diabetes Care Inc. | Method and system for providing analyte monitoring |
US9833181B2 (en) | 2006-08-09 | 2017-12-05 | Abbot Diabetes Care Inc. | Method and system for providing calibration of an analyte sensor in an analyte monitoring system |
US9882660B2 (en) | 2006-10-26 | 2018-01-30 | Abbott Diabetes Care Inc. | Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors |
US9907492B2 (en) | 2012-09-26 | 2018-03-06 | Abbott Diabetes Care Inc. | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
US9913600B2 (en) | 2007-06-29 | 2018-03-13 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
US9931075B2 (en) | 2008-05-30 | 2018-04-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US9936910B2 (en) | 2009-07-31 | 2018-04-10 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte monitoring and therapy management system accuracy |
US9943644B2 (en) | 2008-08-31 | 2018-04-17 | Abbott Diabetes Care Inc. | Closed loop control with reference measurement and methods thereof |
US9949678B2 (en) | 2007-05-08 | 2018-04-24 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
US9968302B2 (en) | 2009-08-31 | 2018-05-15 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
US9980670B2 (en) | 2002-11-05 | 2018-05-29 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
US9980669B2 (en) | 2011-11-07 | 2018-05-29 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
US10002233B2 (en) | 2007-05-14 | 2018-06-19 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10009244B2 (en) | 2009-04-15 | 2018-06-26 | Abbott Diabetes Care Inc. | Analyte monitoring system having an alert |
CN108226078A (en) * | 2018-02-11 | 2018-06-29 | 中国环境科学研究院 | The adjustable ultraviolet-visible spectrum in-situ monitoring device of light path and multi-parameter water-quality measuring method |
US10022499B2 (en) | 2007-02-15 | 2018-07-17 | Abbott Diabetes Care Inc. | Device and method for automatic data acquisition and/or detection |
US10031002B2 (en) | 2007-05-14 | 2018-07-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10028680B2 (en) | 2006-04-28 | 2018-07-24 | Abbott Diabetes Care Inc. | Introducer assembly and methods of use |
US10039881B2 (en) | 2002-12-31 | 2018-08-07 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US10045720B2 (en) | 2007-05-14 | 2018-08-14 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10045739B2 (en) | 2008-09-30 | 2018-08-14 | Abbott Diabetes Care Inc. | Analyte sensor sensitivity attenuation mitigation |
US10076285B2 (en) | 2013-03-15 | 2018-09-18 | Abbott Diabetes Care Inc. | Sensor fault detection using analyte sensor data pattern comparison |
US10082493B2 (en) | 2011-11-25 | 2018-09-25 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods of use |
US10089446B2 (en) | 2009-01-29 | 2018-10-02 | Abbott Diabetes Care Inc. | Method and device for providing offset model based calibration for analyte sensor |
US10092229B2 (en) | 2010-06-29 | 2018-10-09 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
US10111608B2 (en) | 2007-04-14 | 2018-10-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US10117614B2 (en) | 2006-02-28 | 2018-11-06 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
US10132793B2 (en) | 2012-08-30 | 2018-11-20 | Abbott Diabetes Care Inc. | Dropout detection in continuous analyte monitoring data during data excursions |
US10136816B2 (en) | 2009-08-31 | 2018-11-27 | Abbott Diabetes Care Inc. | Medical devices and methods |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
US10173007B2 (en) | 2007-10-23 | 2019-01-08 | Abbott Diabetes Care Inc. | Closed loop control system with safety parameters and methods |
US10194863B2 (en) | 2005-09-30 | 2019-02-05 | Abbott Diabetes Care Inc. | Integrated transmitter unit and sensor introducer mechanism and methods of use |
US10201301B2 (en) | 2005-11-01 | 2019-02-12 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10226207B2 (en) | 2004-12-29 | 2019-03-12 | Abbott Diabetes Care Inc. | Sensor inserter having introducer |
US10328201B2 (en) | 2008-07-14 | 2019-06-25 | Abbott Diabetes Care Inc. | Closed loop control system interface and methods |
US10349877B2 (en) | 2007-04-14 | 2019-07-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US10429250B2 (en) | 2009-08-31 | 2019-10-01 | Abbott Diabetes Care, Inc. | Analyte monitoring system and methods for managing power and noise |
US10433773B1 (en) | 2013-03-15 | 2019-10-08 | Abbott Diabetes Care Inc. | Noise rejection methods and apparatus for sparsely sampled analyte sensor data |
US10463310B2 (en) | 2007-05-14 | 2019-11-05 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10478108B2 (en) | 1998-04-30 | 2019-11-19 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10555695B2 (en) | 2011-04-15 | 2020-02-11 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US10610135B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
USD902408S1 (en) | 2003-11-05 | 2020-11-17 | Abbott Diabetes Care Inc. | Analyte sensor control unit |
US10874338B2 (en) | 2010-06-29 | 2020-12-29 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US10874336B2 (en) | 2013-03-15 | 2020-12-29 | Abbott Diabetes Care Inc. | Multi-rate analyte sensor data collection with sample rate configurable signal processing |
US10991456B2 (en) | 2007-05-14 | 2021-04-27 | Abbott Diabetes Care Inc. | Method and system for determining analyte levels |
US11000215B1 (en) | 2003-12-05 | 2021-05-11 | Dexcom, Inc. | Analyte sensor |
USD924406S1 (en) | 2010-02-01 | 2021-07-06 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
US11213226B2 (en) | 2010-10-07 | 2022-01-04 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods |
US11229382B2 (en) | 2013-12-31 | 2022-01-25 | Abbott Diabetes Care Inc. | Self-powered analyte sensor and devices using the same |
US11264133B2 (en) | 2007-06-21 | 2022-03-01 | Abbott Diabetes Care Inc. | Health management devices and methods |
US11298058B2 (en) | 2005-12-28 | 2022-04-12 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US11350862B2 (en) | 2017-10-24 | 2022-06-07 | Dexcom, Inc. | Pre-connected analyte sensors |
USD961778S1 (en) | 2006-02-28 | 2022-08-23 | Abbott Diabetes Care Inc. | Analyte sensor device |
US11553883B2 (en) | 2015-07-10 | 2023-01-17 | Abbott Diabetes Care Inc. | System, device and method of dynamic glucose profile response to physiological parameters |
US11596330B2 (en) | 2017-03-21 | 2023-03-07 | Abbott Diabetes Care Inc. | Methods, devices and system for providing diabetic condition diagnosis and therapy |
USD980986S1 (en) | 2015-05-14 | 2023-03-14 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
USD982762S1 (en) | 2020-12-21 | 2023-04-04 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
US11717225B2 (en) | 2014-03-30 | 2023-08-08 | Abbott Diabetes Care Inc. | Method and apparatus for determining meal start and peak events in analyte monitoring systems |
USD1002852S1 (en) | 2019-06-06 | 2023-10-24 | Abbott Diabetes Care Inc. | Analyte sensor device |
US11793936B2 (en) | 2009-05-29 | 2023-10-24 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
US11883164B2 (en) | 2004-07-13 | 2024-01-30 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
Families Citing this family (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
EP2077444A3 (en) * | 2000-09-25 | 2009-11-04 | Panasonic Corporation | Chromatography quantitative measuring apparatus |
JP2004535834A (en) * | 2000-11-16 | 2004-12-02 | カメレオン・メディカル・イノベーション・リミテッド | Ear diagnostic system |
WO2004023974A2 (en) * | 2002-09-10 | 2004-03-25 | Euro-Celtique, S.A. | Apparatus and method for non-invasive measurement of blood constituents |
CN100483106C (en) * | 2002-09-29 | 2009-04-29 | 天津市先石光学技术有限公司 | Optical method for detecting discerptible medium skin layer and deep layer information |
US7248912B2 (en) * | 2002-10-31 | 2007-07-24 | The Regents Of The University Of California | Tissue implantable sensors for measurement of blood solutes |
WO2004069164A2 (en) * | 2003-01-30 | 2004-08-19 | Euro Celtique Sa | Wireless blood glucose monitoring system |
US7283242B2 (en) * | 2003-04-11 | 2007-10-16 | Thornton Robert L | Optical spectroscopy apparatus and method for measurement of analyte concentrations or other such species in a specimen employing a semiconductor laser-pumped, small-cavity fiber laser |
US7633621B2 (en) * | 2003-04-11 | 2009-12-15 | Thornton Robert L | Method for measurement of analyte concentrations and semiconductor laser-pumped, small-cavity fiber lasers for such measurements and other applications |
US7214190B1 (en) | 2003-09-09 | 2007-05-08 | Kitchener Clark Wilson | Apparatus and method for noninvasive monitoring of analytes in body fluids |
US20050165622A1 (en) * | 2004-01-26 | 2005-07-28 | Neel Gary T. | Medical diagnostic testing device with voice message capability |
JP2007519484A (en) * | 2004-01-27 | 2007-07-19 | アルティベラ・リミテッド・ライアビリティ・カンパニー | Diagnostic radio frequency identification sensor and its application |
CA2460898A1 (en) * | 2004-03-09 | 2005-09-09 | James Samsoondar | Apparatus and method for combining in vivo and in vitro testing |
WO2005106017A2 (en) * | 2004-04-21 | 2005-11-10 | University Of Virginia Patent Foundation | Method, system and computer program product for evaluating the accuracy of blood glucose monitoring sensors/devices |
CA2572455C (en) | 2004-06-04 | 2014-10-28 | Therasense, Inc. | Diabetes care host-client architecture and data management system |
WO2006009906A2 (en) * | 2004-06-17 | 2006-01-26 | The Regents Of The University Of California | Time-resolved non-invasive autofluorescence device for detecting diabetes |
WO2006009910A2 (en) * | 2004-06-17 | 2006-01-26 | The Regents Of The University Of California | Time-resolved optometric fluorescence detection for skin diagnostics |
IL163796A0 (en) * | 2004-08-30 | 2005-12-18 | Gribova Orna A | Device for detecting changes in blood glucose level or dardiovacular condition |
US9572534B2 (en) | 2010-06-29 | 2017-02-21 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US9398882B2 (en) | 2005-09-30 | 2016-07-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor and data processing device |
CA2517299A1 (en) * | 2005-08-26 | 2007-02-26 | Chromedx Inc. | Hollow needle assembly |
US8206650B2 (en) * | 2005-04-12 | 2012-06-26 | Chromedx Inc. | Joint-diagnostic spectroscopic and biosensor meter |
US20100245803A1 (en) * | 2005-04-12 | 2010-09-30 | Chromedx Inc. | Blood sample holder for spectroscopic analysis |
CA2507323A1 (en) | 2005-05-13 | 2006-11-13 | Chromedx Inc. | Diagnostic whole blood and plasma apparatus |
US7409239B2 (en) * | 2005-05-05 | 2008-08-05 | The Hong Kong Polytechnic University | Method for predicting the blood glucose level of a person |
US20070027374A1 (en) * | 2005-05-19 | 2007-02-01 | Foss Analytical Ab | Optical blood analyte monitor |
US7330747B2 (en) * | 2005-06-07 | 2008-02-12 | Chemimage Corporation | Invasive chemometry |
US7330746B2 (en) * | 2005-06-07 | 2008-02-12 | Chem Image Corporation | Non-invasive biochemical analysis |
CA2616376A1 (en) * | 2005-07-25 | 2007-02-01 | Duke University | Methods, systems, and computer program products for optimization of probes for spectroscopic measurement in turbid media |
CN102440785A (en) | 2005-08-31 | 2012-05-09 | 弗吉尼亚大学专利基金委员会 | Sensor signal processing method and sensor signal processing device |
US9521968B2 (en) | 2005-09-30 | 2016-12-20 | Abbott Diabetes Care Inc. | Analyte sensor retention mechanism and methods of use |
US8880138B2 (en) | 2005-09-30 | 2014-11-04 | Abbott Diabetes Care Inc. | Device for channeling fluid and methods of use |
US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
US20070136099A1 (en) * | 2005-12-13 | 2007-06-14 | Gordon Neligh | Distributed medicine system |
US7736310B2 (en) | 2006-01-30 | 2010-06-15 | Abbott Diabetes Care Inc. | On-body medical device securement |
CA2644620A1 (en) * | 2006-03-01 | 2007-09-07 | G.R. Enlightenment Ltd. | Apparatus and method for measuring parameters associated with electrochemical processes |
US8583205B2 (en) | 2008-03-28 | 2013-11-12 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US9392969B2 (en) | 2008-08-31 | 2016-07-19 | Abbott Diabetes Care Inc. | Closed loop control and signal attenuation detection |
EP2030210A4 (en) | 2006-04-12 | 2010-04-14 | Proteus Biomedical Inc | Void-free implantable hermetically sealed structures |
US20070253380A1 (en) * | 2006-04-28 | 2007-11-01 | James Jollota | Data translation device with nonvolatile memory for a networked medical device system |
US20070255126A1 (en) * | 2006-04-28 | 2007-11-01 | Moberg Sheldon B | Data communication in networked fluid infusion systems |
US8348885B2 (en) * | 2006-04-28 | 2013-01-08 | Medtronic Minimed, Inc. | Remote monitoring for networked fluid infusion systems |
US20070288266A1 (en) * | 2006-06-02 | 2007-12-13 | Suzanne Sysko | System and methods for chronic disease management and health assessment |
US7486976B1 (en) | 2006-07-25 | 2009-02-03 | Edward Belotserkovsky | Optical non-invasive blood monitoring system and method |
US8326390B2 (en) * | 2006-07-25 | 2012-12-04 | Edward Belotserkovsky | Optical non-invasive blood monitoring system and method |
US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
US8732188B2 (en) * | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
WO2008103827A1 (en) | 2007-02-22 | 2008-08-28 | Welldoc Communications, Inc. | System and method for providing treatment recommendations based on models |
US10872686B2 (en) | 2007-02-22 | 2020-12-22 | WellDoc, Inc. | Systems and methods for disease control and management |
US10860943B2 (en) | 2007-02-22 | 2020-12-08 | WellDoc, Inc. | Systems and methods for disease control and management |
US9204827B2 (en) | 2007-04-14 | 2015-12-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US7928850B2 (en) | 2007-05-08 | 2011-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8461985B2 (en) | 2007-05-08 | 2013-06-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US20080312845A1 (en) * | 2007-05-14 | 2008-12-18 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8026382B2 (en) * | 2007-05-18 | 2011-09-27 | Heidi Kay | Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods |
US8602997B2 (en) | 2007-06-12 | 2013-12-10 | Sotera Wireless, Inc. | Body-worn system for measuring continuous non-invasive blood pressure (cNIBP) |
US11607152B2 (en) | 2007-06-12 | 2023-03-21 | Sotera Wireless, Inc. | Optical sensors for use in vital sign monitoring |
US11330988B2 (en) | 2007-06-12 | 2022-05-17 | Sotera Wireless, Inc. | Body-worn system for measuring continuous non-invasive blood pressure (cNIBP) |
EP2162059B1 (en) | 2007-06-12 | 2021-01-13 | Sotera Wireless, Inc. | Vital sign monitor and method for measuring blood pressure using optical, electrical, and pressure waveforms |
JP5260903B2 (en) * | 2007-07-06 | 2013-08-14 | 株式会社東芝 | Automatic analyzer |
US8834366B2 (en) | 2007-07-31 | 2014-09-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor calibration |
US20090036760A1 (en) * | 2007-07-31 | 2009-02-05 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9820655B2 (en) * | 2007-09-28 | 2017-11-21 | Duke University | Systems and methods for spectral analysis of a tissue mass using an instrument, an optical probe, and a Monte Carlo or a diffusion algorithm |
WO2009061367A2 (en) * | 2007-11-05 | 2009-05-14 | Biosensor, Inc. | Optical sensor for determining the concentration of an analyte |
US20090164239A1 (en) * | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Dynamic Display Of Glucose Information |
US20090164190A1 (en) * | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Physiological condition simulation device and method |
JP2009168748A (en) * | 2008-01-18 | 2009-07-30 | Sumitomo Electric Ind Ltd | Apparatus for inspecting food |
MY179050A (en) * | 2008-04-04 | 2020-10-26 | Colgate Palmolive Co | Analysis of substrates having agents deposited thereon |
US20110105865A1 (en) * | 2008-04-24 | 2011-05-05 | Duke University | Diffuse reflectance spectroscopy device for quantifying tissue absorption and scattering |
US7826382B2 (en) | 2008-05-30 | 2010-11-02 | Abbott Diabetes Care Inc. | Close proximity communication device and methods |
US20100057040A1 (en) | 2008-08-31 | 2010-03-04 | Abbott Diabetes Care, Inc. | Robust Closed Loop Control And Methods |
US8622988B2 (en) * | 2008-08-31 | 2014-01-07 | Abbott Diabetes Care Inc. | Variable rate closed loop control and methods |
US9229233B2 (en) | 2014-02-11 | 2016-01-05 | Osterhout Group, Inc. | Micro Doppler presentations in head worn computing |
US9298007B2 (en) | 2014-01-21 | 2016-03-29 | Osterhout Group, Inc. | Eye imaging in head worn computing |
US20100198196A1 (en) * | 2009-01-30 | 2010-08-05 | Abbott Diabetes Care, Inc. | Therapy Delivery Device Programming Tool |
US8560082B2 (en) * | 2009-01-30 | 2013-10-15 | Abbott Diabetes Care Inc. | Computerized determination of insulin pump therapy parameters using real time and retrospective data processing |
EP4252639A3 (en) * | 2009-02-26 | 2024-01-03 | Abbott Diabetes Care Inc. | Method of calibrating an analyte sensor |
WO2010127052A1 (en) * | 2009-04-28 | 2010-11-04 | Abbott Diabetes Care Inc. | Dynamic analyte sensor calibration based on sensor stability profile |
US9226701B2 (en) | 2009-04-28 | 2016-01-05 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
EP2425209A4 (en) | 2009-04-29 | 2013-01-09 | Abbott Diabetes Care Inc | Method and system for providing real time analyte sensor calibration with retrospective backfill |
US11896350B2 (en) | 2009-05-20 | 2024-02-13 | Sotera Wireless, Inc. | Cable system for generating signals for detecting motion and measuring vital signs |
US10973414B2 (en) | 2009-05-20 | 2021-04-13 | Sotera Wireless, Inc. | Vital sign monitoring system featuring 3 accelerometers |
US8956294B2 (en) | 2009-05-20 | 2015-02-17 | Sotera Wireless, Inc. | Body-worn system for continuously monitoring a patients BP, HR, SpO2, RR, temperature, and motion; also describes specific monitors for apnea, ASY, VTAC, VFIB, and ‘bed sore’ index |
US9596999B2 (en) * | 2009-06-17 | 2017-03-21 | Sotera Wireless, Inc. | Body-worn pulse oximeter |
US10475529B2 (en) | 2011-07-19 | 2019-11-12 | Optiscan Biomedical Corporation | Method and apparatus for analyte measurements using calibration sets |
EP2456351B1 (en) * | 2009-07-23 | 2016-10-12 | Abbott Diabetes Care, Inc. | Real time management of data relating to physiological control of glucose levels |
US10123722B2 (en) | 2009-09-14 | 2018-11-13 | Sotera Wireless, Inc. | Body-worn monitor for measuring respiration rate |
US20110066043A1 (en) * | 2009-09-14 | 2011-03-17 | Matt Banet | System for measuring vital signs during hemodialysis |
US11253169B2 (en) | 2009-09-14 | 2022-02-22 | Sotera Wireless, Inc. | Body-worn monitor for measuring respiration rate |
US10420476B2 (en) | 2009-09-15 | 2019-09-24 | Sotera Wireless, Inc. | Body-worn vital sign monitor |
US10806351B2 (en) | 2009-09-15 | 2020-10-20 | Sotera Wireless, Inc. | Body-worn vital sign monitor |
US8527038B2 (en) * | 2009-09-15 | 2013-09-03 | Sotera Wireless, Inc. | Body-worn vital sign monitor |
WO2011091336A1 (en) * | 2010-01-22 | 2011-07-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification in analyte monitoring systems |
WO2011112753A1 (en) | 2010-03-10 | 2011-09-15 | Abbott Diabetes Care Inc. | Systems, devices and methods for managing glucose levels |
US20110224564A1 (en) | 2010-03-10 | 2011-09-15 | Sotera Wireless, Inc. | Body-worn vital sign monitor |
US9339209B2 (en) | 2010-04-19 | 2016-05-17 | Sotera Wireless, Inc. | Body-worn monitor for measuring respiratory rate |
US8747330B2 (en) | 2010-04-19 | 2014-06-10 | Sotera Wireless, Inc. | Body-worn monitor for measuring respiratory rate |
US9173594B2 (en) | 2010-04-19 | 2015-11-03 | Sotera Wireless, Inc. | Body-worn monitor for measuring respiratory rate |
US8888700B2 (en) | 2010-04-19 | 2014-11-18 | Sotera Wireless, Inc. | Body-worn monitor for measuring respiratory rate |
US8979765B2 (en) | 2010-04-19 | 2015-03-17 | Sotera Wireless, Inc. | Body-worn monitor for measuring respiratory rate |
US9173593B2 (en) | 2010-04-19 | 2015-11-03 | Sotera Wireless, Inc. | Body-worn monitor for measuring respiratory rate |
US8635046B2 (en) | 2010-06-23 | 2014-01-21 | Abbott Diabetes Care Inc. | Method and system for evaluating analyte sensor response characteristics |
US20120226117A1 (en) * | 2010-12-01 | 2012-09-06 | Lamego Marcelo M | Handheld processing device including medical applications for minimally and non invasive glucose measurements |
US20140249432A1 (en) | 2010-12-28 | 2014-09-04 | Matt Banet | Body-worn system for continuous, noninvasive measurement of cardiac output, stroke volume, cardiac power, and blood pressure |
US10357187B2 (en) | 2011-02-18 | 2019-07-23 | Sotera Wireless, Inc. | Optical sensor for measuring physiological properties |
WO2012112891A1 (en) | 2011-02-18 | 2012-08-23 | Sotera Wireless, Inc. | Modular wrist-worn processor for patient monitoring |
CA3177983A1 (en) | 2011-02-28 | 2012-11-15 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
US9238133B2 (en) | 2011-05-09 | 2016-01-19 | The Invention Science Fund I, Llc | Method, device and system for modulating an activity of brown adipose tissue in a vertebrate subject |
US8690934B2 (en) | 2011-05-09 | 2014-04-08 | The Invention Science Fund I, Llc | Method, device and system for modulating an activity of brown adipose tissue in a vertebrate subject |
KR20140082642A (en) | 2011-07-26 | 2014-07-02 | 글리젠스 인코포레이티드 | Tissue implantable sensor with hermetically sealed housing |
JP5730253B2 (en) * | 2011-09-27 | 2015-06-03 | 富士フイルム株式会社 | Laser light source unit and photoacoustic image generation apparatus |
AU2012330761B2 (en) | 2011-11-03 | 2016-01-21 | Verifood Ltd. | Low-cost spectrometry system for end-user food analysis |
US9317656B2 (en) | 2011-11-23 | 2016-04-19 | Abbott Diabetes Care Inc. | Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof |
US10561353B2 (en) | 2016-06-01 | 2020-02-18 | Glysens Incorporated | Biocompatible implantable sensor apparatus and methods |
US10660550B2 (en) | 2015-12-29 | 2020-05-26 | Glysens Incorporated | Implantable sensor apparatus and methods |
US20140275870A1 (en) * | 2013-03-15 | 2014-09-18 | Grove Instruments Inc. | Continuous noninvasive measurement of analyte concentration using an optical bridge |
EP3028020B1 (en) | 2013-08-02 | 2021-11-24 | Verifood Ltd. | Spectrometry system |
EP3090239A4 (en) * | 2014-01-03 | 2018-01-10 | Verifood Ltd. | Spectrometry systems, methods, and applications |
US20150228119A1 (en) | 2014-02-11 | 2015-08-13 | Osterhout Group, Inc. | Spatial location presentation in head worn computing |
US10684687B2 (en) | 2014-12-03 | 2020-06-16 | Mentor Acquisition One, Llc | See-through computer display systems |
WO2015109145A1 (en) | 2014-01-17 | 2015-07-23 | Osterhout Group, Inc. | See-through computer display systems |
US11487110B2 (en) | 2014-01-21 | 2022-11-01 | Mentor Acquisition One, Llc | Eye imaging in head worn computing |
US9753288B2 (en) | 2014-01-21 | 2017-09-05 | Osterhout Group, Inc. | See-through computer display systems |
US9494800B2 (en) | 2014-01-21 | 2016-11-15 | Osterhout Group, Inc. | See-through computer display systems |
US9766463B2 (en) | 2014-01-21 | 2017-09-19 | Osterhout Group, Inc. | See-through computer display systems |
US9852545B2 (en) | 2014-02-11 | 2017-12-26 | Osterhout Group, Inc. | Spatial location presentation in head worn computing |
US9401540B2 (en) | 2014-02-11 | 2016-07-26 | Osterhout Group, Inc. | Spatial location presentation in head worn computing |
EP3074753A1 (en) * | 2014-02-19 | 2016-10-05 | Halliburton Energy Services, Inc. | Integrated computational element designed for multi-characteristic detection |
US20160187651A1 (en) | 2014-03-28 | 2016-06-30 | Osterhout Group, Inc. | Safety for a vehicle operator with an hmd |
EP3151906B1 (en) | 2014-06-03 | 2019-12-11 | Pop Test Abuse Deterrent Technology LLC | Drug device configured for wireless communication |
US9459201B2 (en) | 2014-09-29 | 2016-10-04 | Zyomed Corp. | Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing |
WO2016063284A2 (en) | 2014-10-23 | 2016-04-28 | Verifood, Ltd. | Accessories for handheld spectrometer |
US20160131904A1 (en) | 2014-11-07 | 2016-05-12 | Osterhout Group, Inc. | Power management for head worn computing |
WO2016125164A2 (en) | 2015-02-05 | 2016-08-11 | Verifood, Ltd. | Spectrometry system applications |
WO2016125165A2 (en) | 2015-02-05 | 2016-08-11 | Verifood, Ltd. | Spectrometry system with visible aiming beam |
US20160239985A1 (en) | 2015-02-17 | 2016-08-18 | Osterhout Group, Inc. | See-through computer display systems |
US10878775B2 (en) | 2015-02-17 | 2020-12-29 | Mentor Acquisition One, Llc | See-through computer display systems |
WO2016183493A1 (en) | 2015-05-14 | 2016-11-17 | Abbott Diabetes Care Inc. | Compact medical device inserters and related systems and methods |
US10066990B2 (en) | 2015-07-09 | 2018-09-04 | Verifood, Ltd. | Spatially variable filter systems and methods |
US10441316B2 (en) | 2015-09-11 | 2019-10-15 | Pop Test LLC | Intradermal applicator/analyte sensor placement using fluorescence |
CN106803009A (en) * | 2015-11-26 | 2017-06-06 | 北京光巨力信息技术有限公司 | A kind of near infrared no-wound blood glucose meter correcting algorithm based on manifold learning and RBF neural |
US10591728B2 (en) | 2016-03-02 | 2020-03-17 | Mentor Acquisition One, Llc | Optical systems for head-worn computers |
US10667981B2 (en) | 2016-02-29 | 2020-06-02 | Mentor Acquisition One, Llc | Reading assistance system for visually impaired |
US9554738B1 (en) | 2016-03-30 | 2017-01-31 | Zyomed Corp. | Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing |
US10638962B2 (en) | 2016-06-29 | 2020-05-05 | Glysens Incorporated | Bio-adaptable implantable sensor apparatus and methods |
WO2018015951A1 (en) | 2016-07-20 | 2018-01-25 | Verifood, Ltd. | Accessories for handheld spectrometer |
US10791933B2 (en) | 2016-07-27 | 2020-10-06 | Verifood, Ltd. | Spectrometry systems, methods, and applications |
US10638979B2 (en) | 2017-07-10 | 2020-05-05 | Glysens Incorporated | Analyte sensor data evaluation and error reduction apparatus and methods |
WO2019012309A1 (en) * | 2017-07-11 | 2019-01-17 | Azure Vault Ltd. | Measuring body fluid content |
US11278668B2 (en) | 2017-12-22 | 2022-03-22 | Glysens Incorporated | Analyte sensor and medicant delivery data evaluation and error reduction apparatus and methods |
US11255839B2 (en) | 2018-01-04 | 2022-02-22 | Glysens Incorporated | Apparatus and methods for analyte sensor mismatch correction |
CN117168619B (en) * | 2023-11-02 | 2024-02-02 | 武汉大学 | Spectrum calibration method and system for satellite-borne hyperspectral imager |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5068536A (en) * | 1989-01-19 | 1991-11-26 | Futrex, Inc. | Method for providing custom calibration for near infrared instruments for measurement of blood glucose |
US5772586A (en) * | 1996-02-12 | 1998-06-30 | Nokia Mobile Phones, Ltd. | Method for monitoring the health of a patient |
US5840020A (en) * | 1996-02-12 | 1998-11-24 | Nokia Mobile Phones, Ltd. | Monitoring method and a monitoring equipment |
US6309884B1 (en) * | 1997-02-26 | 2001-10-30 | Diasense, Inc. | Individual calibration of blood glucose for supporting noninvasive self-monitoring blood glucose |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0160768B1 (en) | 1984-05-04 | 1989-05-03 | Kurabo Industries Ltd. | Spectrophotometric apparatus for the non-invasive determination of glucose in body tissues |
EP0236023A3 (en) | 1986-03-03 | 1988-09-07 | Seymour Norman Blackman | Non-invasive blood glucose level monitoring method |
US4935346A (en) | 1986-08-13 | 1990-06-19 | Lifescan, Inc. | Minimum procedure system for the determination of analytes |
US4766551A (en) | 1986-09-22 | 1988-08-23 | Pacific Scientific Company | Method of comparing spectra to identify similar materials |
US5362307A (en) | 1989-01-24 | 1994-11-08 | The Regents Of The University Of California | Method for the iontophoretic non-invasive-determination of the in vivo concentration level of an inorganic or organic substance |
US5121338A (en) | 1988-03-10 | 1992-06-09 | Indiana University Foundation | Method for detecting subpopulations in spectral analysis |
US5009230A (en) | 1988-05-31 | 1991-04-23 | Eol, Inc. | Personal glucose monitor |
US4901728A (en) | 1988-05-31 | 1990-02-20 | Eol, Inc. | Personal glucose monitor |
US5361758A (en) | 1988-06-09 | 1994-11-08 | Cme Telemetrix Inc. | Method and device for measuring concentration levels of blood constituents non-invasively |
US5782755A (en) | 1993-11-15 | 1998-07-21 | Non-Invasive Technology, Inc. | Monitoring one or more solutes in a biological system using optical techniques |
US5077476A (en) | 1990-06-27 | 1991-12-31 | Futrex, Inc. | Instrument for non-invasive measurement of blood glucose |
US5204532A (en) | 1989-01-19 | 1993-04-20 | Futrex, Inc. | Method for providing general calibration for near infrared instruments for measurement of blood glucose |
US5086229A (en) | 1989-01-19 | 1992-02-04 | Futrex, Inc. | Non-invasive measurement of blood glucose |
US6066847A (en) | 1989-01-19 | 2000-05-23 | Futrex Inc. | Procedure for verifying the accuracy of non-invasive blood glucose measurement instruments |
US5028787A (en) | 1989-01-19 | 1991-07-02 | Futrex, Inc. | Non-invasive measurement of blood glucose |
FI90592C (en) | 1989-02-16 | 1994-02-25 | Anadis Instr Sa | IR spectrometric analysis method and IR spectrometer |
DK0385805T3 (en) | 1989-03-03 | 1996-09-23 | Edward W Stark | Method and apparatus for signal processing |
US5137023A (en) | 1990-04-19 | 1992-08-11 | Worcester Polytechnic Institute | Method and apparatus for monitoring blood analytes noninvasively by pulsatile photoplethysmography |
US5139023A (en) | 1989-06-02 | 1992-08-18 | Theratech Inc. | Apparatus and method for noninvasive blood glucose monitoring |
US4975581A (en) | 1989-06-21 | 1990-12-04 | University Of New Mexico | Method of and apparatus for determining the similarity of a biological analyte from a model constructed from known biological fluids |
US5101814A (en) | 1989-08-11 | 1992-04-07 | Palti Yoram Prof | System for monitoring and controlling blood glucose |
US5568400A (en) | 1989-09-01 | 1996-10-22 | Stark; Edward W. | Multiplicative signal correction method and apparatus |
JP3213307B2 (en) | 1989-09-18 | 2001-10-02 | ミネソタ マイニング アンド マニユフアクチユアリング カンパニー | A method for predicting the properties of biological materials by near-infrared spectral analysis |
CA2025330C (en) | 1989-09-18 | 2002-01-22 | David W. Osten | Characterizing biological matter in a dynamic condition using near infrared spectroscopy |
CA2028261C (en) | 1989-10-28 | 1995-01-17 | Won Suck Yang | Non-invasive method and apparatus for measuring blood glucose concentration |
US5140985A (en) | 1989-12-11 | 1992-08-25 | Schroeder Jon M | Noninvasive blood glucose measuring device |
US5070874A (en) | 1990-01-30 | 1991-12-10 | Biocontrol Technology, Inc. | Non-invasive determination of glucose concentration in body of patients |
US5349188A (en) | 1990-04-09 | 1994-09-20 | Ashland Oil, Inc. | Near infrared analysis of piano constituents and octane number of hydrocarbons |
US5712481A (en) | 1990-04-09 | 1998-01-27 | Ashland Inc | Process and apparatus for analysis of hydrocarbon species by near infrared spectroscopy |
US5119819A (en) | 1990-05-02 | 1992-06-09 | Miles Inc. | Method and apparatus for non-invasive monitoring of blood glucose |
DE69112994T2 (en) | 1990-06-04 | 1996-02-15 | Eastman Kodak Co | METHOD FOR INTERACTIONAL SELF-MODELING ANALYSIS OF MIXTURES. |
US5267151A (en) | 1990-09-07 | 1993-11-30 | Ham Frederic M | Method and apparatus for detecting and identifying a condition |
US5459677A (en) | 1990-10-09 | 1995-10-17 | Board Of Regents Of The University Of Washington | Calibration transfer for analytical instruments |
MY107650A (en) | 1990-10-12 | 1996-05-30 | Exxon Res & Engineering Company | Method of estimating property and / or composition data of a test sample |
US5243546A (en) | 1991-01-10 | 1993-09-07 | Ashland Oil, Inc. | Spectroscopic instrument calibration |
GB9106672D0 (en) | 1991-03-28 | 1991-05-15 | Abbey Biosystems Ltd | Method and apparatus for glucose concentration monitoring |
US5203328A (en) | 1991-07-17 | 1993-04-20 | Georgia Tech Research Corporation | Apparatus and methods for quantitatively measuring molecular changes in the ocular lens |
US5299138A (en) | 1991-08-09 | 1994-03-29 | The United States Of America As Represented By The Secretary Of Commerce | Desk top spectrum analyzer |
US5206701A (en) | 1991-09-20 | 1993-04-27 | Amoco Corporation | Apparatus for near-infrared spectrophotometric analysis |
US5223715A (en) | 1991-09-20 | 1993-06-29 | Amoco Corporation | Process for spectrophotometric analysis |
DK165391D0 (en) | 1991-09-27 | 1991-09-27 | Foss Electric As | IR measurement system |
US5258825A (en) | 1991-11-13 | 1993-11-02 | Perten Instruments North America, Inc. | Optical compositional analyzer apparatus and method for detection of ash in wheat and milled wheat products |
US5223714A (en) | 1991-11-26 | 1993-06-29 | Ashland Oil, Inc. | Process for predicting properties of multi-component fluid blends |
US5242602A (en) | 1992-03-04 | 1993-09-07 | W. R. Grace & Co.-Conn. | Spectrophotometric monitoring of multiple water treatment performance indicators using chemometrics |
US5370114A (en) | 1992-03-12 | 1994-12-06 | Wong; Jacob Y. | Non-invasive blood chemistry measurement by stimulated infrared relaxation emission |
DK39792D0 (en) | 1992-03-25 | 1992-03-25 | Foss Electric As | PROCEDURE FOR DETERMINING A COMPONENT |
NL9200731A (en) | 1992-04-22 | 1993-11-16 | Jacob Korf | METHOD AND APPARATUS FOR NON-INVASIVE MONITORING OF THE CONCENTRATION OF SUBSTANCES IN BLOOD. |
US5348002A (en) | 1992-04-23 | 1994-09-20 | Sirraya, Inc. | Method and apparatus for material analysis |
US5672875A (en) | 1992-07-15 | 1997-09-30 | Optix Lp | Methods of minimizing scattering and improving tissue sampling in non-invasive testing and imaging |
US5348003A (en) | 1992-09-03 | 1994-09-20 | Sirraya, Inc. | Method and apparatus for chemical analysis |
US5433197A (en) | 1992-09-04 | 1995-07-18 | Stark; Edward W. | Non-invasive glucose measurement method and apparatus |
IL107396A (en) | 1992-11-09 | 1997-02-18 | Boehringer Mannheim Gmbh | Method and apparatus for analytical determination of glucose in a biological matrix |
US5307263A (en) | 1992-11-17 | 1994-04-26 | Raya Systems, Inc. | Modular microprocessor-based health monitoring system |
US5379764A (en) | 1992-12-09 | 1995-01-10 | Diasense, Inc. | Non-invasive determination of analyte concentration in body of mammals |
US5313941A (en) | 1993-01-28 | 1994-05-24 | Braig James R | Noninvasive pulsed infrared spectrophotometer |
US5515847A (en) | 1993-01-28 | 1996-05-14 | Optiscan, Inc. | Self-emission noninvasive infrared spectrophotometer |
US5615672A (en) | 1993-01-28 | 1997-04-01 | Optiscan, Inc. | Self-emission noninvasive infrared spectrophotometer with body temperature compensation |
DE69430152T2 (en) | 1993-06-25 | 2002-10-31 | Edward W Stark | Method and device for measuring glucose-related substances |
US5383452A (en) | 1993-07-01 | 1995-01-24 | Buchert; Janusz | Method, apparatus and procedure for non-invasive monitoring blood glucose by measuring the polarization ratio of blood luminescence |
US5435309A (en) | 1993-08-10 | 1995-07-25 | Thomas; Edward V. | Systematic wavelength selection for improved multivariate spectral analysis |
US5360972A (en) | 1993-08-17 | 1994-11-01 | Western Atlas International, Inc. | Method for improving chemometric estimations of properties of materials |
EP0683641A4 (en) | 1993-08-24 | 1998-07-15 | Mark R Robinson | A robust accurate non-invasive analyte monitor. |
US5456252A (en) | 1993-09-30 | 1995-10-10 | Cedars-Sinai Medical Center | Induced fluorescence spectroscopy blood perfusion and pH monitor and method |
DE4337570A1 (en) | 1993-11-04 | 1995-05-11 | Boehringer Mannheim Gmbh | Method for the analysis of glucose in a biological matrix |
US5459317A (en) | 1994-02-14 | 1995-10-17 | Ohio University | Method and apparatus for non-invasive detection of physiological chemicals, particularly glucose |
TW275570B (en) | 1994-05-05 | 1996-05-11 | Boehringer Mannheim Gmbh | |
DE4415896A1 (en) | 1994-05-05 | 1995-11-09 | Boehringer Mannheim Gmbh | Analysis system for monitoring the concentration of an analyte in the blood of a patient |
SE9401718L (en) | 1994-05-18 | 1995-11-19 | Eka Nobel Ab | Ways to determine the parameters in paper |
US5498875A (en) | 1994-08-17 | 1996-03-12 | Beckman Instruments, Inc. | Signal processing for chemical analysis of samples |
EP0706050A1 (en) | 1994-10-07 | 1996-04-10 | Bp Chemicals S.N.C. | Lubricant property determination |
EP0706040A1 (en) | 1994-10-07 | 1996-04-10 | Bp Chemicals S.N.C. | Property determination |
US5900634A (en) | 1994-11-14 | 1999-05-04 | Soloman; Sabrie | Real-time on-line analysis of organic and non-organic compounds for food, fertilizers, and pharmaceutical products |
US5641962A (en) | 1995-12-05 | 1997-06-24 | Exxon Research And Engineering Company | Non linear multivariate infrared analysis method (LAW362) |
US5512751A (en) | 1994-12-19 | 1996-04-30 | Uop | Calibration of NIR spectra in measuring properties of petroleum products |
NZ300915A (en) | 1995-02-09 | 1998-12-23 | Foss Electric As | Method for standardizing a spectrometer generating an optical spectrum from a sample |
US5841523A (en) | 1995-04-20 | 1998-11-24 | Chiron Diagnostics Corporation | Method for performing spectroscopic analysis of inhomogeneous test samples |
US5752512A (en) | 1995-05-10 | 1998-05-19 | Massachusetts Institute Of Technology | Apparatus and method for non-invasive blood analyte measurement |
US6070128A (en) | 1995-06-06 | 2000-05-30 | Eutech Engineering Solutions Limited | Method for determining properties using near infra-red (NIR) spectroscopy |
US5638816A (en) | 1995-06-07 | 1997-06-17 | Masimo Corporation | Active pulse blood constituent monitoring |
US5743262A (en) | 1995-06-07 | 1998-04-28 | Masimo Corporation | Blood glucose monitoring system |
GB2301897B (en) | 1995-06-08 | 1999-05-26 | Univ Wales Aberystwyth The | Composition analysis |
US5602755A (en) | 1995-06-23 | 1997-02-11 | Exxon Research And Engineering Company | Method for predicting chemical or physical properties of complex mixtures |
US5657754A (en) | 1995-07-10 | 1997-08-19 | Rosencwaig; Allan | Apparatus for non-invasive analyses of biological compounds |
SG38866A1 (en) | 1995-07-31 | 1997-04-17 | Instrumentation Metrics Inc | Liquid correlation spectrometry |
US5606164A (en) | 1996-01-16 | 1997-02-25 | Boehringer Mannheim Corporation | Method and apparatus for biological fluid analyte concentration measurement using generalized distance outlier detection |
US5655530A (en) | 1995-08-09 | 1997-08-12 | Rio Grande Medical Technologies, Inc. | Method for non-invasive blood analyte measurement with improved optical interface |
US5636633A (en) | 1995-08-09 | 1997-06-10 | Rio Grande Medical Technologies, Inc. | Diffuse reflectance monitoring apparatus |
ATE396644T1 (en) | 1995-12-19 | 2008-06-15 | Abbott Lab | DEVICE FOR DETECTING AN ANALYTE AND ADMINISTERING A THERAPEUTIC SUBSTANCE |
DE19548378A1 (en) | 1995-12-27 | 1997-07-03 | Bran & Luebbe | Process and device combination for establishing the comparability of spectrometer measurements |
US5610836A (en) | 1996-01-31 | 1997-03-11 | Eastman Chemical Company | Process to use multivariate signal responses to analyze a sample |
US6040578A (en) | 1996-02-02 | 2000-03-21 | Instrumentation Metrics, Inc. | Method and apparatus for multi-spectral analysis of organic blood analytes in noninvasive infrared spectroscopy |
US5747806A (en) | 1996-02-02 | 1998-05-05 | Instrumentation Metrics, Inc | Method and apparatus for multi-spectral analysis in noninvasive nir spectroscopy |
ATE209017T1 (en) | 1996-02-05 | 2001-12-15 | Diasense Inc | DEVICE FOR THE NON-INVASIVE DETERMINATION OF GLUCOSE |
US5788632A (en) | 1996-03-19 | 1998-08-04 | Abbott Laboratories | Apparatus and process for the non-invasive measurement of optically active compounds |
US5890489A (en) | 1996-04-23 | 1999-04-06 | Dermal Therapy (Barbados) Inc. | Method for non-invasive determination of glucose in body fluids |
US5668373A (en) | 1996-04-26 | 1997-09-16 | Trustees Of Tufts College | Methods and apparatus for analysis of complex mixtures |
US5668374A (en) | 1996-05-07 | 1997-09-16 | Core Laboratories N.V. | Method for stabilizing near-infrared models and determining their applicability |
US5822219A (en) | 1996-05-13 | 1998-10-13 | Foss Nirsystems, Inc. | System for identifying materials by NIR spectrometry |
US5666956A (en) | 1996-05-20 | 1997-09-16 | Buchert; Janusz Michal | Instrument and method for non-invasive monitoring of human tissue analyte by measuring the body's infrared radiation |
FR2754899B1 (en) | 1996-10-23 | 1998-11-27 | Elf Antar France | METHOD OF MONITORING AND MONITORING A MANUFACTURING UNIT AND / OR A NEAR INFRARED SPECTROMETER USING A QUALITY CRITERION OF SPECTRUM SETS |
TW342447B (en) | 1996-11-11 | 1998-10-11 | Cherng Jou | Noninvasive polarized common path optical heterodyne glucose monitoring system |
US5798526A (en) | 1997-01-24 | 1998-08-25 | Infrasoft International Llc | Calibration system for spectrographic analyzing instruments |
US5910109A (en) | 1997-02-20 | 1999-06-08 | Emerging Technology Systems, Llc | Non-invasive glucose measuring device and method for measuring blood glucose |
US6161028A (en) | 1999-03-10 | 2000-12-12 | Optiscan Biomedical Corporation | Method for determining analyte concentration using periodic temperature modulation and phase detection |
US5823966A (en) | 1997-05-20 | 1998-10-20 | Buchert; Janusz Michal | Non-invasive continuous blood glucose monitoring |
US5985120A (en) | 1997-06-12 | 1999-11-16 | University Of Massachusetts | Rapid analysis of analyte solutions |
US6115673A (en) | 1997-08-14 | 2000-09-05 | Instrumentation Metrics, Inc. | Method and apparatus for generating basis sets for use in spectroscopic analysis |
US5946128A (en) | 1997-08-15 | 1999-08-31 | The United States Of America As Represented By The Secretary Of Commerce | Grating assisted acousto-optic tunable filter and method |
GB2329015B (en) | 1997-09-05 | 2002-02-13 | Samsung Electronics Co Ltd | Method and device for noninvasive measurement of concentrations of blood components |
US6114699A (en) | 1997-11-26 | 2000-09-05 | The United States Of America As Represented By The Secretary Of Agriculture | Prediction of total dietary fiber in cereal products using near-infrared reflectance spectroscopy |
US6006119A (en) | 1998-02-04 | 1999-12-21 | Polestar Technologies, Inc. | Non-invasive optical measurement of blood hematocrit |
US6087662A (en) | 1998-05-22 | 2000-07-11 | Marathon Ashland Petroleum Llc | Process for analysis of asphaltene content in hydrocarbon mixtures by middle infrared spectroscopy |
US6064897A (en) | 1998-06-01 | 2000-05-16 | Abbott Laboratories | Sensor utilizing Raman spectroscopy for non-invasive monitoring of analytes in biological fluid and method of use |
US6137108A (en) | 1998-06-17 | 2000-10-24 | Foss Nirsystems Incorporated | Instrument and method for spectroscopic analysis by reflectance and transmittance |
AU4986899A (en) | 1998-07-13 | 2000-02-01 | Children's Hospital Of Los Angeles | Non-invasive glucose monitor |
US6248067B1 (en) * | 1999-02-05 | 2001-06-19 | Minimed Inc. | Analyte sensor and holter-type monitor system and method of using the same |
US6087182A (en) | 1998-08-27 | 2000-07-11 | Abbott Laboratories | Reagentless analysis of biological samples |
US6091843A (en) | 1998-09-03 | 2000-07-18 | Greenvision Systems Ltd. | Method of calibration and real-time analysis of particulates |
US6157041A (en) | 1998-10-13 | 2000-12-05 | Rio Grande Medical Technologies, Inc. | Methods and apparatus for tailoring spectroscopic calibration models |
US6159255A (en) | 1998-12-11 | 2000-12-12 | Sunoco, Inc. (R&M) | Method for predicting intrinsic properties of a mixture |
US6067463A (en) | 1999-01-05 | 2000-05-23 | Abbott Laboratories | Method and apparatus for non-invasively measuring the amount of glucose in blood |
US6151517A (en) | 1999-01-22 | 2000-11-21 | Futrex Inc. | Method and apparatus for noninvasive quantitative measurement of blood analytes |
-
2001
- 2001-08-17 EP EP01968013A patent/EP1311189A4/en not_active Withdrawn
- 2001-08-17 WO PCT/US2001/025810 patent/WO2002016905A2/en not_active Application Discontinuation
- 2001-08-17 US US09/932,185 patent/US6675030B2/en not_active Expired - Fee Related
- 2001-08-17 AU AU2001288292A patent/AU2001288292A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5068536A (en) * | 1989-01-19 | 1991-11-26 | Futrex, Inc. | Method for providing custom calibration for near infrared instruments for measurement of blood glucose |
US5772586A (en) * | 1996-02-12 | 1998-06-30 | Nokia Mobile Phones, Ltd. | Method for monitoring the health of a patient |
US5840020A (en) * | 1996-02-12 | 1998-11-24 | Nokia Mobile Phones, Ltd. | Monitoring method and a monitoring equipment |
US6309884B1 (en) * | 1997-02-26 | 2001-10-30 | Diasense, Inc. | Individual calibration of blood glucose for supporting noninvasive self-monitoring blood glucose |
Non-Patent Citations (1)
Title |
---|
See also references of EP1311189A2 * |
Cited By (308)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9042953B2 (en) | 1998-04-30 | 2015-05-26 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066694B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10478108B2 (en) | 1998-04-30 | 2019-11-19 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066697B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9610034B2 (en) | 2001-01-02 | 2017-04-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9498159B2 (en) | 2001-01-02 | 2016-11-22 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US7183102B2 (en) | 2002-03-08 | 2007-02-27 | Sensys Medical, Inc. | Apparatus using reference measurement for calibration |
CN100335002C (en) * | 2002-03-08 | 2007-09-05 | 三西斯医学股份有限公司 | Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers |
EP1509126A4 (en) * | 2002-03-08 | 2008-05-07 | Sensys Medical Inc | Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers |
WO2003076893A2 (en) * | 2002-03-08 | 2003-09-18 | Sensys Medical, Inc. | Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers |
US6998247B2 (en) | 2002-03-08 | 2006-02-14 | Sensys Medical, Inc. | Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers |
JP2005519683A (en) * | 2002-03-08 | 2005-07-07 | センシス メディカル インク | Method and apparatus for calibrating and maintaining non-invasive and implantable analyzers using alternative site glucose quantification |
EP1509126A2 (en) * | 2002-03-08 | 2005-03-02 | Sensys Medical, Inc. | Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers |
WO2003076893A3 (en) * | 2002-03-08 | 2004-12-16 | Sensys Medical Inc | Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers |
US11141084B2 (en) | 2002-11-05 | 2021-10-12 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
US9980670B2 (en) | 2002-11-05 | 2018-05-29 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
US10973443B2 (en) | 2002-11-05 | 2021-04-13 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
US11116430B2 (en) | 2002-11-05 | 2021-09-14 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
US10750952B2 (en) | 2002-12-31 | 2020-08-25 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
US10039881B2 (en) | 2002-12-31 | 2018-08-07 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US9962091B2 (en) | 2002-12-31 | 2018-05-08 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
US7811231B2 (en) | 2002-12-31 | 2010-10-12 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
US9730584B2 (en) | 2003-06-10 | 2017-08-15 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
US7299082B2 (en) | 2003-10-31 | 2007-11-20 | Abbott Diabetes Care, Inc. | Method of calibrating an analyte-measurement device, and associated methods, devices and systems |
USD902408S1 (en) | 2003-11-05 | 2020-11-17 | Abbott Diabetes Care Inc. | Analyte sensor control unit |
USD914881S1 (en) | 2003-11-05 | 2021-03-30 | Abbott Diabetes Care Inc. | Analyte sensor electronic mount |
US11627900B2 (en) | 2003-12-05 | 2023-04-18 | Dexcom, Inc. | Analyte sensor |
US11000215B1 (en) | 2003-12-05 | 2021-05-11 | Dexcom, Inc. | Analyte sensor |
US11020031B1 (en) | 2003-12-05 | 2021-06-01 | Dexcom, Inc. | Analyte sensor |
US11883164B2 (en) | 2004-07-13 | 2024-01-30 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US7728821B2 (en) | 2004-08-06 | 2010-06-01 | Touchtable, Inc. | Touch detecting interactive display |
US10073610B2 (en) | 2004-08-06 | 2018-09-11 | Qualcomm Incorporated | Bounding box gesture recognition on a touch detecting interactive display |
US8624863B2 (en) | 2004-08-06 | 2014-01-07 | Qualcomm Incorporated | Touch driven method and apparatus to integrate and display multiple image layers forming alternate depictions of same subject matter |
US8669958B2 (en) | 2004-08-06 | 2014-03-11 | Qualcomm Incorporated | Method and apparatus continuing action of user gestures performed upon a touch sensitive interactive display in simulation of inertia |
US8692792B2 (en) | 2004-08-06 | 2014-04-08 | Qualcomm Incorporated | Bounding box gesture recognition on a touch detecting interactive display |
WO2006056024A1 (en) * | 2004-11-29 | 2006-06-01 | Scientific Analytics Systems Pty Ltd | Modelling a phenomenon that has spectral data |
US10226207B2 (en) | 2004-12-29 | 2019-03-12 | Abbott Diabetes Care Inc. | Sensor inserter having introducer |
US11160475B2 (en) | 2004-12-29 | 2021-11-02 | Abbott Diabetes Care Inc. | Sensor inserter having introducer |
US10918317B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610136B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US11051726B2 (en) | 2005-03-10 | 2021-07-06 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US11000213B2 (en) | 2005-03-10 | 2021-05-11 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10856787B2 (en) | 2005-03-10 | 2020-12-08 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918318B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918316B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610135B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10925524B2 (en) | 2005-03-10 | 2021-02-23 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10898114B2 (en) | 2005-03-10 | 2021-01-26 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610137B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10709364B2 (en) | 2005-03-10 | 2020-07-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10716498B2 (en) | 2005-03-10 | 2020-07-21 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10617336B2 (en) | 2005-03-10 | 2020-04-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10743801B2 (en) | 2005-03-10 | 2020-08-18 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10194863B2 (en) | 2005-09-30 | 2019-02-05 | Abbott Diabetes Care Inc. | Integrated transmitter unit and sensor introducer mechanism and methods of use |
US9775563B2 (en) | 2005-09-30 | 2017-10-03 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
US10342489B2 (en) | 2005-09-30 | 2019-07-09 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
US11103165B2 (en) | 2005-11-01 | 2021-08-31 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11272867B2 (en) | 2005-11-01 | 2022-03-15 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11399748B2 (en) | 2005-11-01 | 2022-08-02 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11363975B2 (en) | 2005-11-01 | 2022-06-21 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10231654B2 (en) | 2005-11-01 | 2019-03-19 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11911151B1 (en) | 2005-11-01 | 2024-02-27 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10952652B2 (en) | 2005-11-01 | 2021-03-23 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10201301B2 (en) | 2005-11-01 | 2019-02-12 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9078607B2 (en) | 2005-11-01 | 2015-07-14 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9795331B2 (en) | 2005-12-28 | 2017-10-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US10307091B2 (en) | 2005-12-28 | 2019-06-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US11298058B2 (en) | 2005-12-28 | 2022-04-12 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US11872039B2 (en) | 2006-02-28 | 2024-01-16 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
US9031630B2 (en) | 2006-02-28 | 2015-05-12 | Abbott Diabetes Care Inc. | Analyte sensors and methods of use |
US9844329B2 (en) | 2006-02-28 | 2017-12-19 | Abbott Diabetes Care Inc. | Analyte sensors and methods of use |
USD961778S1 (en) | 2006-02-28 | 2022-08-23 | Abbott Diabetes Care Inc. | Analyte sensor device |
US10117614B2 (en) | 2006-02-28 | 2018-11-06 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
US9743863B2 (en) | 2006-03-31 | 2017-08-29 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
US9039975B2 (en) | 2006-03-31 | 2015-05-26 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
US9625413B2 (en) | 2006-03-31 | 2017-04-18 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
US10028680B2 (en) | 2006-04-28 | 2018-07-24 | Abbott Diabetes Care Inc. | Introducer assembly and methods of use |
US10736547B2 (en) | 2006-04-28 | 2020-08-11 | Abbott Diabetes Care Inc. | Introducer assembly and methods of use |
US11864894B2 (en) | 2006-08-09 | 2024-01-09 | Abbott Diabetes Care Inc. | Method and system for providing calibration of an analyte sensor in an analyte monitoring system |
US10278630B2 (en) | 2006-08-09 | 2019-05-07 | Abbott Diabetes Care Inc. | Method and system for providing calibration of an analyte sensor in an analyte monitoring system |
US9833181B2 (en) | 2006-08-09 | 2017-12-05 | Abbot Diabetes Care Inc. | Method and system for providing calibration of an analyte sensor in an analyte monitoring system |
US9808186B2 (en) | 2006-09-10 | 2017-11-07 | Abbott Diabetes Care Inc. | Method and system for providing an integrated analyte sensor insertion device and data processing unit |
US9629578B2 (en) | 2006-10-02 | 2017-04-25 | Abbott Diabetes Care Inc. | Method and system for dynamically updating calibration parameters for an analyte sensor |
US9839383B2 (en) | 2006-10-02 | 2017-12-12 | Abbott Diabetes Care Inc. | Method and system for dynamically updating calibration parameters for an analyte sensor |
US10342469B2 (en) | 2006-10-02 | 2019-07-09 | Abbott Diabetes Care Inc. | Method and system for dynamically updating calibration parameters for an analyte sensor |
US9788771B2 (en) | 2006-10-23 | 2017-10-17 | Abbott Diabetes Care Inc. | Variable speed sensor insertion devices and methods of use |
US10194868B2 (en) | 2006-10-25 | 2019-02-05 | Abbott Diabetes Care Inc. | Method and system for providing analyte monitoring |
US11282603B2 (en) | 2006-10-25 | 2022-03-22 | Abbott Diabetes Care Inc. | Method and system for providing analyte monitoring |
US9814428B2 (en) | 2006-10-25 | 2017-11-14 | Abbott Diabetes Care Inc. | Method and system for providing analyte monitoring |
US10903914B2 (en) | 2006-10-26 | 2021-01-26 | Abbott Diabetes Care Inc. | Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors |
US9882660B2 (en) | 2006-10-26 | 2018-01-30 | Abbott Diabetes Care Inc. | Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors |
US11722229B2 (en) | 2006-10-26 | 2023-08-08 | Abbott Diabetes Care Inc. | Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors |
US10617823B2 (en) | 2007-02-15 | 2020-04-14 | Abbott Diabetes Care Inc. | Device and method for automatic data acquisition and/or detection |
US10022499B2 (en) | 2007-02-15 | 2018-07-17 | Abbott Diabetes Care Inc. | Device and method for automatic data acquisition and/or detection |
US9636450B2 (en) | 2007-02-19 | 2017-05-02 | Udo Hoss | Pump system modular components for delivering medication and analyte sensing at seperate insertion sites |
US9801545B2 (en) | 2007-03-01 | 2017-10-31 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
US10194846B2 (en) | 2007-04-14 | 2019-02-05 | Abbott Diabetes Care Inc. | Method and apparatus for providing dynamic multi-stage signal amplification in a medical device |
US9615780B2 (en) | 2007-04-14 | 2017-04-11 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US11039767B2 (en) | 2007-04-14 | 2021-06-22 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US8937540B2 (en) | 2007-04-14 | 2015-01-20 | Abbott Diabetes Care Inc. | Method and apparatus for providing dynamic multi-stage signal amplification in a medical device |
US10111608B2 (en) | 2007-04-14 | 2018-10-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US10349877B2 (en) | 2007-04-14 | 2019-07-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US9743866B2 (en) | 2007-04-14 | 2017-08-29 | Abbott Diabetes Care Inc. | Method and apparatus for providing dynamic multi-stage signal amplification in a medical device |
US9949678B2 (en) | 2007-05-08 | 2018-04-24 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
US9649057B2 (en) | 2007-05-08 | 2017-05-16 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US10653317B2 (en) | 2007-05-08 | 2020-05-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US11696684B2 (en) | 2007-05-08 | 2023-07-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US10952611B2 (en) | 2007-05-08 | 2021-03-23 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US10178954B2 (en) | 2007-05-08 | 2019-01-15 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US9797880B2 (en) | 2007-05-14 | 2017-10-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9737249B2 (en) | 2007-05-14 | 2017-08-22 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US11125592B2 (en) | 2007-05-14 | 2021-09-21 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10976304B2 (en) | 2007-05-14 | 2021-04-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US11119090B2 (en) | 2007-05-14 | 2021-09-14 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9804150B2 (en) | 2007-05-14 | 2017-10-31 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10143409B2 (en) | 2007-05-14 | 2018-12-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10463310B2 (en) | 2007-05-14 | 2019-11-05 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10119956B2 (en) | 2007-05-14 | 2018-11-06 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9801571B2 (en) | 2007-05-14 | 2017-10-31 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US11076785B2 (en) | 2007-05-14 | 2021-08-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10002233B2 (en) | 2007-05-14 | 2018-06-19 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10991456B2 (en) | 2007-05-14 | 2021-04-27 | Abbott Diabetes Care Inc. | Method and system for determining analyte levels |
US10653344B2 (en) | 2007-05-14 | 2020-05-19 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10634662B2 (en) | 2007-05-14 | 2020-04-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10820841B2 (en) | 2007-05-14 | 2020-11-03 | Abbot Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10045720B2 (en) | 2007-05-14 | 2018-08-14 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US11300561B2 (en) | 2007-05-14 | 2022-04-12 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10261069B2 (en) | 2007-05-14 | 2019-04-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10031002B2 (en) | 2007-05-14 | 2018-07-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9060719B2 (en) | 2007-05-14 | 2015-06-23 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US11828748B2 (en) | 2007-05-14 | 2023-11-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US11264133B2 (en) | 2007-06-21 | 2022-03-01 | Abbott Diabetes Care Inc. | Health management devices and methods |
US11276492B2 (en) | 2007-06-21 | 2022-03-15 | Abbott Diabetes Care Inc. | Health management devices and methods |
US11678821B2 (en) | 2007-06-29 | 2023-06-20 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
US10856785B2 (en) | 2007-06-29 | 2020-12-08 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
US9913600B2 (en) | 2007-06-29 | 2018-03-13 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
US9743865B2 (en) | 2007-10-23 | 2017-08-29 | Abbott Diabetes Care Inc. | Assessing measures of glycemic variability |
US10173007B2 (en) | 2007-10-23 | 2019-01-08 | Abbott Diabetes Care Inc. | Closed loop control system with safety parameters and methods |
US9804148B2 (en) | 2007-10-23 | 2017-10-31 | Abbott Diabetes Care Inc. | Analyte sensor with lag compensation |
US11083843B2 (en) | 2007-10-23 | 2021-08-10 | Abbott Diabetes Care Inc. | Closed loop control system with safety parameters and methods |
US9770211B2 (en) | 2008-01-31 | 2017-09-26 | Abbott Diabetes Care Inc. | Analyte sensor with time lag compensation |
US11779248B2 (en) | 2008-03-28 | 2023-10-10 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US10463288B2 (en) | 2008-03-28 | 2019-11-05 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US9730623B2 (en) | 2008-03-28 | 2017-08-15 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US11735295B2 (en) | 2008-05-30 | 2023-08-22 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US9931075B2 (en) | 2008-05-30 | 2018-04-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US10327682B2 (en) | 2008-05-30 | 2019-06-25 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US9795328B2 (en) | 2008-05-30 | 2017-10-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US10328201B2 (en) | 2008-07-14 | 2019-06-25 | Abbott Diabetes Care Inc. | Closed loop control system interface and methods |
US11621073B2 (en) | 2008-07-14 | 2023-04-04 | Abbott Diabetes Care Inc. | Closed loop control system interface and methods |
US9610046B2 (en) | 2008-08-31 | 2017-04-04 | Abbott Diabetes Care Inc. | Closed loop control with improved alarm functions |
US9943644B2 (en) | 2008-08-31 | 2018-04-17 | Abbott Diabetes Care Inc. | Closed loop control with reference measurement and methods thereof |
US11464434B2 (en) | 2008-09-30 | 2022-10-11 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
US11013439B2 (en) | 2008-09-30 | 2021-05-25 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
US11202592B2 (en) | 2008-09-30 | 2021-12-21 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
US9662056B2 (en) | 2008-09-30 | 2017-05-30 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
US11484234B2 (en) | 2008-09-30 | 2022-11-01 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
US10045739B2 (en) | 2008-09-30 | 2018-08-14 | Abbott Diabetes Care Inc. | Analyte sensor sensitivity attenuation mitigation |
US10980461B2 (en) | 2008-11-07 | 2021-04-20 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US11272890B2 (en) | 2008-11-10 | 2022-03-15 | Abbott Diabetes Care Inc. | Alarm characterization for analyte monitoring devices and systems |
US9730650B2 (en) | 2008-11-10 | 2017-08-15 | Abbott Diabetes Care Inc. | Alarm characterization for analyte monitoring devices and systems |
US11678848B2 (en) | 2008-11-10 | 2023-06-20 | Abbott Diabetes Care Inc. | Alarm characterization for analyte monitoring devices and systems |
US10089446B2 (en) | 2009-01-29 | 2018-10-02 | Abbott Diabetes Care Inc. | Method and device for providing offset model based calibration for analyte sensor |
US11464430B2 (en) | 2009-01-29 | 2022-10-11 | Abbott Diabetes Care Inc. | Method and device for providing offset model based calibration for analyte sensor |
US9066709B2 (en) | 2009-01-29 | 2015-06-30 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
US11213229B2 (en) | 2009-02-03 | 2022-01-04 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
USD882432S1 (en) | 2009-02-03 | 2020-04-28 | Abbott Diabetes Care Inc. | Analyte sensor on body unit |
US9993188B2 (en) | 2009-02-03 | 2018-06-12 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
USD957643S1 (en) | 2009-02-03 | 2022-07-12 | Abbott Diabetes Care Inc. | Analyte sensor device |
US11202591B2 (en) | 2009-02-03 | 2021-12-21 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US10786190B2 (en) | 2009-02-03 | 2020-09-29 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US11166656B2 (en) | 2009-02-03 | 2021-11-09 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US9636068B2 (en) | 2009-02-03 | 2017-05-02 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US11006871B2 (en) | 2009-02-03 | 2021-05-18 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US11006870B2 (en) | 2009-02-03 | 2021-05-18 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US11006872B2 (en) | 2009-02-03 | 2021-05-18 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
USD957642S1 (en) | 2009-02-03 | 2022-07-12 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
US10009244B2 (en) | 2009-04-15 | 2018-06-26 | Abbott Diabetes Care Inc. | Analyte monitoring system having an alert |
US10617296B2 (en) | 2009-04-29 | 2020-04-14 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US9949639B2 (en) | 2009-04-29 | 2018-04-24 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US10172518B2 (en) | 2009-04-29 | 2019-01-08 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US9088452B2 (en) | 2009-04-29 | 2015-07-21 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US9693688B2 (en) | 2009-04-29 | 2017-07-04 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US11872370B2 (en) | 2009-05-29 | 2024-01-16 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
US11793936B2 (en) | 2009-05-29 | 2023-10-24 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
US9795326B2 (en) | 2009-07-23 | 2017-10-24 | Abbott Diabetes Care Inc. | Continuous analyte measurement systems and systems and methods for implanting them |
US10827954B2 (en) | 2009-07-23 | 2020-11-10 | Abbott Diabetes Care Inc. | Continuous analyte measurement systems and systems and methods for implanting them |
US10660554B2 (en) | 2009-07-31 | 2020-05-26 | Abbott Diabetes Care Inc. | Methods and devices for analyte monitoring calibration |
US11234625B2 (en) | 2009-07-31 | 2022-02-01 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte monitoring and therapy management system accuracy |
US9936910B2 (en) | 2009-07-31 | 2018-04-10 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte monitoring and therapy management system accuracy |
US10136816B2 (en) | 2009-08-31 | 2018-11-27 | Abbott Diabetes Care Inc. | Medical devices and methods |
US10123752B2 (en) | 2009-08-31 | 2018-11-13 | Abbott Diabetes Care Inc. | Displays for a medical device |
US11241175B2 (en) | 2009-08-31 | 2022-02-08 | Abbott Diabetes Care Inc. | Displays for a medical device |
US11635332B2 (en) | 2009-08-31 | 2023-04-25 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
US11202586B2 (en) | 2009-08-31 | 2021-12-21 | Abbott Diabetes Care Inc. | Displays for a medical device |
US9968302B2 (en) | 2009-08-31 | 2018-05-15 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
US11150145B2 (en) | 2009-08-31 | 2021-10-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
US10881355B2 (en) | 2009-08-31 | 2021-01-05 | Abbott Diabetes Care Inc. | Displays for a medical device |
USD1010133S1 (en) | 2009-08-31 | 2024-01-02 | Abbott Diabetes Care Inc. | Analyte sensor assembly |
USRE47315E1 (en) | 2009-08-31 | 2019-03-26 | Abbott Diabetes Care Inc. | Displays for a medical device |
US9814416B2 (en) | 2009-08-31 | 2017-11-14 | Abbott Diabetes Care Inc. | Displays for a medical device |
US11730429B2 (en) | 2009-08-31 | 2023-08-22 | Abbott Diabetes Care Inc. | Displays for a medical device |
US11045147B2 (en) | 2009-08-31 | 2021-06-29 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
USD962446S1 (en) | 2009-08-31 | 2022-08-30 | Abbott Diabetes Care, Inc. | Analyte sensor device |
US10772572B2 (en) | 2009-08-31 | 2020-09-15 | Abbott Diabetes Care Inc. | Displays for a medical device |
US10429250B2 (en) | 2009-08-31 | 2019-10-01 | Abbott Diabetes Care, Inc. | Analyte monitoring system and methods for managing power and noise |
US10918342B1 (en) | 2009-08-31 | 2021-02-16 | Abbott Diabetes Care Inc. | Displays for a medical device |
US10456091B2 (en) | 2009-08-31 | 2019-10-29 | Abbott Diabetes Care Inc. | Displays for a medical device |
US10492685B2 (en) | 2009-08-31 | 2019-12-03 | Abbott Diabetes Care Inc. | Medical devices and methods |
US9750439B2 (en) | 2009-09-29 | 2017-09-05 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
US10349874B2 (en) | 2009-09-29 | 2019-07-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
US9750444B2 (en) | 2009-09-30 | 2017-09-05 | Abbott Diabetes Care Inc. | Interconnect for on-body analyte monitoring device |
US11259725B2 (en) | 2009-09-30 | 2022-03-01 | Abbott Diabetes Care Inc. | Interconnect for on-body analyte monitoring device |
US10765351B2 (en) | 2009-09-30 | 2020-09-08 | Abbott Diabetes Care Inc. | Interconnect for on-body analyte monitoring device |
US10117606B2 (en) | 2009-10-30 | 2018-11-06 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
US9050041B2 (en) | 2009-10-30 | 2015-06-09 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
US11207005B2 (en) | 2009-10-30 | 2021-12-28 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
USD924406S1 (en) | 2010-02-01 | 2021-07-06 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
US9687183B2 (en) | 2010-03-24 | 2017-06-27 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
USD948722S1 (en) | 2010-03-24 | 2022-04-12 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
US10945649B2 (en) | 2010-03-24 | 2021-03-16 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
USD987830S1 (en) | 2010-03-24 | 2023-05-30 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
US10959654B2 (en) | 2010-03-24 | 2021-03-30 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US10292632B2 (en) | 2010-03-24 | 2019-05-21 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US11058334B1 (en) | 2010-03-24 | 2021-07-13 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US11246519B2 (en) | 2010-03-24 | 2022-02-15 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US11013440B2 (en) | 2010-03-24 | 2021-05-25 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
USD997362S1 (en) | 2010-03-24 | 2023-08-29 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
US11064922B1 (en) | 2010-03-24 | 2021-07-20 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US11000216B2 (en) | 2010-03-24 | 2021-05-11 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US10881340B2 (en) | 2010-03-24 | 2021-01-05 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US11266335B2 (en) | 2010-03-24 | 2022-03-08 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US10952657B2 (en) | 2010-03-24 | 2021-03-23 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US10881341B1 (en) | 2010-03-24 | 2021-01-05 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US10010280B2 (en) | 2010-03-24 | 2018-07-03 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US10772547B1 (en) | 2010-03-24 | 2020-09-15 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US10092229B2 (en) | 2010-06-29 | 2018-10-09 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
US11064921B2 (en) | 2010-06-29 | 2021-07-20 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US10959653B2 (en) | 2010-06-29 | 2021-03-30 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US10966644B2 (en) | 2010-06-29 | 2021-04-06 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US10973449B2 (en) | 2010-06-29 | 2021-04-13 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US11478173B2 (en) | 2010-06-29 | 2022-10-25 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
US10874338B2 (en) | 2010-06-29 | 2020-12-29 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US11213226B2 (en) | 2010-10-07 | 2022-01-04 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods |
WO2012049666A2 (en) | 2010-10-15 | 2012-04-19 | Verrana, Llc | Data word analysis by spectroscopy |
US8517274B2 (en) | 2010-10-15 | 2013-08-27 | Verrana Llc | Data word analysis by spectroscopy |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
US11627898B2 (en) | 2011-02-28 | 2023-04-18 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
US11534089B2 (en) | 2011-02-28 | 2022-12-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
US9743862B2 (en) | 2011-03-31 | 2017-08-29 | Abbott Diabetes Care Inc. | Systems and methods for transcutaneously implanting medical devices |
US10624568B2 (en) | 2011-04-15 | 2020-04-21 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US10610141B2 (en) | 2011-04-15 | 2020-04-07 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US10561354B2 (en) | 2011-04-15 | 2020-02-18 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US10555695B2 (en) | 2011-04-15 | 2020-02-11 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US10835162B2 (en) | 2011-04-15 | 2020-11-17 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US10682084B2 (en) | 2011-04-15 | 2020-06-16 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US10722162B2 (en) | 2011-04-15 | 2020-07-28 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US9069536B2 (en) | 2011-10-31 | 2015-06-30 | Abbott Diabetes Care Inc. | Electronic devices having integrated reset systems and methods thereof |
US9913619B2 (en) | 2011-10-31 | 2018-03-13 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
US9622691B2 (en) | 2011-10-31 | 2017-04-18 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
US11406331B2 (en) | 2011-10-31 | 2022-08-09 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
US9980669B2 (en) | 2011-11-07 | 2018-05-29 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
US10136847B2 (en) | 2011-11-23 | 2018-11-27 | Abbott Diabetes Care Inc. | Mitigating single point failure of devices in an analyte monitoring system and methods thereof |
US10939859B2 (en) | 2011-11-23 | 2021-03-09 | Abbott Diabetes Care Inc. | Mitigating single point failure of devices in an analyte monitoring system and methods thereof |
US9743872B2 (en) | 2011-11-23 | 2017-08-29 | Abbott Diabetes Care Inc. | Mitigating single point failure of devices in an analyte monitoring system and methods thereof |
US10082493B2 (en) | 2011-11-25 | 2018-09-25 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods of use |
US11391723B2 (en) | 2011-11-25 | 2022-07-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods of use |
US9931066B2 (en) | 2011-12-11 | 2018-04-03 | Abbott Diabetes Care Inc. | Analyte sensor devices, connections, and methods |
US11051724B2 (en) | 2011-12-11 | 2021-07-06 | Abbott Diabetes Care Inc. | Analyte sensor devices, connections, and methods |
USD915602S1 (en) | 2011-12-11 | 2021-04-06 | Abbott Diabetes Care Inc. | Analyte sensor device |
US9693713B2 (en) | 2011-12-11 | 2017-07-04 | Abbott Diabetes Care Inc. | Analyte sensor devices, connections, and methods |
US11051725B2 (en) | 2011-12-11 | 2021-07-06 | Abbott Diabetes Care Inc. | Analyte sensor devices, connections, and methods |
USD903877S1 (en) | 2011-12-11 | 2020-12-01 | Abbott Diabetes Care Inc. | Analyte sensor device |
US11179068B2 (en) | 2011-12-11 | 2021-11-23 | Abbott Diabetes Care Inc. | Analyte sensor devices, connections, and methods |
USD915601S1 (en) | 2011-12-11 | 2021-04-06 | Abbott Diabetes Care Inc. | Analyte sensor device |
US10656139B2 (en) | 2012-08-30 | 2020-05-19 | Abbott Diabetes Care Inc. | Dropout detection in continuous analyte monitoring data during data excursions |
US10132793B2 (en) | 2012-08-30 | 2018-11-20 | Abbott Diabetes Care Inc. | Dropout detection in continuous analyte monitoring data during data excursions |
US10345291B2 (en) | 2012-08-30 | 2019-07-09 | Abbott Diabetes Care Inc. | Dropout detection in continuous analyte monitoring data during data excursions |
US10942164B2 (en) | 2012-08-30 | 2021-03-09 | Abbott Diabetes Care Inc. | Dropout detection in continuous analyte monitoring data during data excursions |
US11612363B2 (en) | 2012-09-17 | 2023-03-28 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
US9907492B2 (en) | 2012-09-26 | 2018-03-06 | Abbott Diabetes Care Inc. | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
US11896371B2 (en) | 2012-09-26 | 2024-02-13 | Abbott Diabetes Care Inc. | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
US10842420B2 (en) | 2012-09-26 | 2020-11-24 | Abbott Diabetes Care Inc. | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
US10188334B2 (en) | 2012-10-30 | 2019-01-29 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
US9675290B2 (en) | 2012-10-30 | 2017-06-13 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
US9801577B2 (en) | 2012-10-30 | 2017-10-31 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
US10076285B2 (en) | 2013-03-15 | 2018-09-18 | Abbott Diabetes Care Inc. | Sensor fault detection using analyte sensor data pattern comparison |
US10874336B2 (en) | 2013-03-15 | 2020-12-29 | Abbott Diabetes Care Inc. | Multi-rate analyte sensor data collection with sample rate configurable signal processing |
US10433773B1 (en) | 2013-03-15 | 2019-10-08 | Abbott Diabetes Care Inc. | Noise rejection methods and apparatus for sparsely sampled analyte sensor data |
US11229382B2 (en) | 2013-12-31 | 2022-01-25 | Abbott Diabetes Care Inc. | Self-powered analyte sensor and devices using the same |
US11717225B2 (en) | 2014-03-30 | 2023-08-08 | Abbott Diabetes Care Inc. | Method and apparatus for determining meal start and peak events in analyte monitoring systems |
EP3128302A4 (en) * | 2014-04-01 | 2017-04-26 | Shimadzu Corporation | Spectrometer and integrating sphere |
US10094711B2 (en) | 2014-04-01 | 2018-10-09 | Shimadzu Corporation | Spectrometer and integrating sphere |
USD980986S1 (en) | 2015-05-14 | 2023-03-14 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
US11553883B2 (en) | 2015-07-10 | 2023-01-17 | Abbott Diabetes Care Inc. | System, device and method of dynamic glucose profile response to physiological parameters |
US11596330B2 (en) | 2017-03-21 | 2023-03-07 | Abbott Diabetes Care Inc. | Methods, devices and system for providing diabetic condition diagnosis and therapy |
US11382540B2 (en) | 2017-10-24 | 2022-07-12 | Dexcom, Inc. | Pre-connected analyte sensors |
US11350862B2 (en) | 2017-10-24 | 2022-06-07 | Dexcom, Inc. | Pre-connected analyte sensors |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US11706876B2 (en) | 2017-10-24 | 2023-07-18 | Dexcom, Inc. | Pre-connected analyte sensors |
US11943876B2 (en) | 2017-10-24 | 2024-03-26 | Dexcom, Inc. | Pre-connected analyte sensors |
CN108226078A (en) * | 2018-02-11 | 2018-06-29 | 中国环境科学研究院 | The adjustable ultraviolet-visible spectrum in-situ monitoring device of light path and multi-parameter water-quality measuring method |
USD1002852S1 (en) | 2019-06-06 | 2023-10-24 | Abbott Diabetes Care Inc. | Analyte sensor device |
USD1006235S1 (en) | 2020-12-21 | 2023-11-28 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
USD999913S1 (en) | 2020-12-21 | 2023-09-26 | Abbott Diabetes Care Inc | Analyte sensor inserter |
USD982762S1 (en) | 2020-12-21 | 2023-04-04 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
Also Published As
Publication number | Publication date |
---|---|
EP1311189A4 (en) | 2005-03-09 |
US20020193671A1 (en) | 2002-12-19 |
AU2001288292A1 (en) | 2002-03-04 |
WO2002016905A3 (en) | 2002-08-01 |
US6675030B2 (en) | 2004-01-06 |
EP1311189A2 (en) | 2003-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6675030B2 (en) | Near infrared blood glucose monitoring system | |
US20050033127A1 (en) | Wireless blood glucose monitoring system | |
US20040133086A1 (en) | Apparatus and method for non-invasive measurement of blood constituents | |
US5379764A (en) | Non-invasive determination of analyte concentration in body of mammals | |
JP4636762B2 (en) | Method for calibrating a spectroscopic device | |
US7698105B2 (en) | Method and apparatus for improving performance of noninvasive analyte property estimation | |
US6898451B2 (en) | Non-invasive blood analyte measuring system and method utilizing optical absorption | |
EP1494577B1 (en) | Spectroscopic analysis of tissue to detect diabetes | |
EP0630203B1 (en) | Non-invasive device and method for determining concentrations of various components of blood or tissue | |
Malin et al. | Noninvasive prediction of glucose by near-infrared diffuse reflectance spectroscopy | |
US6788965B2 (en) | Intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and tissue analytes | |
US6983176B2 (en) | Optically similar reference samples and related methods for multivariate calibration models used in optical spectroscopy | |
JP2002310908A (en) | Method and device for multiple spectrum analysis for non-invasive infrared spectroscopy | |
EP0757243A1 (en) | Liquid correlation spectometry | |
JP2002236097A (en) | Method and apparatus for multi-spectral analysis in noninvasive near-infrared spectroscopy | |
US6919566B1 (en) | Method of calibrating a spectroscopic device | |
US20020095075A1 (en) | Photonic molecular probe applications | |
US6615151B1 (en) | Method for creating spectral instrument variation tolerance in calibration algorithms | |
US20060211926A1 (en) | Non-invasive Raman measurement apparatus with broadband spectral correction | |
EP1553399B1 (en) | Body fluid components measuring apparatus and method | |
JPH09159606A (en) | Liquid-correlation spectrometry | |
Lam et al. | Non-invasive blood glucose measurement by near infrared spectroscopy: Machine drift, time drift and physiological effect | |
KR20050078924A (en) | Urine component analysis system and method by raman spectroscopy | |
JP4563075B2 (en) | Blood glucose level measuring device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001968013 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001968013 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001968013 Country of ref document: EP |